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In this dissertation we consider the dynamics of drug resistance in cancer
and the related issue of the dynamics of cancer stem cells. Our focus is only on
resistance which is caused by random genetic point mutations. A very simple system
of ordinary differential equations allows us to obtain results that are comparable to
those found in the literature with one important difference. We show that the
amount of resistance that is generated before the beginning of the treatment, and
which is present at some given time afterward, always depends on the turnover rate,
no matter how many drugs are used. Previous work in the literature indicated no
dependence on the turnover rate in the single drug case while a strong dependence
in the multi-drug case.
We develop a new methodology in order to derive an estimate of the probability
of developing resistance to drugs by the time a tumor is diagnosed and the expected
number of drug-resistant cells found at detection if resistance is present at detection.
Our modeling methodology may be seen as more general than previous approaches,
in the sense that at least for the wild-type population we make assumptions only
on their averaged behavior (no Markov property for example). Importantly, the
heterogeneity of the cancer population is taken into account. Moreover, in the case
of chronic myeloid leukemia (CML), which is a cancer of the white blood cells, we
are able to infer the preferred mode of division of the hematopoietic cancer stem
cells, predicting a large shift from asymmetric division to symmetric renewal. We
extend our results by relaxing the assumption on the average growth of the tumor,
thus going beyond the standard exponential case, and showing that our results may
be a good approximation also for much more general forms of tumor growth models.
Finally, after reviewing the basic modeling assumptions and main results found
in the mathematical modeling literature on chronic myeloid leukemia (CML), we
formulate a new hypothesis on the effects that the drug Imatinib has on leukemic
stem cells. Specifically, we hypothesize that Imatinib is able to stop leukemic stem
cells from dividing, putting them in a quiescent state. We elucidate the reasons
why this hypothesis can explain the available data on CML better than all other
previous assumptions made in the existing literature. Based on this hypothesis, we
obtain new insights on the dynamics of the development of drug resistance in CML.
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In this dissertation we consider the dynamics of drug resistance in cancer and
the related issue of the dynamics of cancer stem cells. In this chapter we introduce
and briefly discuss relevant biological aspects needed for the mathematical modeling
of these topics.
1.1 Cancer as an evolutionary process and the cancer stem cell hy-
pothesis
Cancer is thought to be monoclonal, that is, to originate from a single cell
that has undergone harmful mutations [41, 85, 57]. These mutations cause the
cell to ignore normal growth controls, thus initiating proliferation [8]. Surprisingly,
the consequent clonal expansion will give rise to a tumor population with a large
heterogeneity. For example, cancer cells within a primary tumor will typically differ
in size, morphology, division rate, death rate, and resistance to a given drug [44, 8].
Only some of this diversity is caused by epigenetic plasticity; there is indeed evidence
of genetic differences within a tumor cell population [91].
There are two fundamental concepts currently used in order to explain the
cause for the observed tumor heterogeneity: the clonal evolution model and the
cancer stem cell hypothesis. As of today, there is supporting evidence for both
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models and it appears that a combination of the two ideas may provide the best
explanation for tumor heterogeneity [91, 8].
The clonal evolution model assumes that a cancer cell has the potential to
become any of the various types of cells present in a tumor. Such a process may
require multiple divisions. The basic mechanism would be given by the well-known
genetic instability of cancer cells [41]. Cancer cells acquire different combinations of
mutations. This will give to different cancer cells different characteristics. Further-
more, some cells will acquire a selective growth advantage over other cancer cells.
The key element of the clonal evolution model is thus given by the occurrence of
various mutations. An important role is played by the genetic drift, i.e., the change
in the frequency of a gene variant in the tumor population due to random sampling
and, even more importantly, by natural selection, where a gene variant may become
more or less common in the tumor population due to their reproductive and survival
abilities [85, 8]. There is evidence of competition, predation, and mutualism within
and around a tumor cell population [71].
On the other hand, the cancer stem cell hypothesis is based on experimental
evidence that many tissues are maintained by a small group of slowly replicating
cells, i. e., by a group of cells which are generally quiescent and only occasionally
dividing [97, 78, 13]. Such relatively rare cells, known as “stem cells”, are defined
by their unique ability of both self-renewal and differentiation into more mature,
specialized cells forming that tissue. This implies a hierarchy among cells, where
only the subset of stem cells has the ability to self-renew while all other cells can only
differentiate into more mature cells or die [78, 87, 118, 69, 119]. Moreover, the subset
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of fully mature, differentiated cells does not have the ability to continue dividing.
Stem cells are also very long lived, while mature, fully differentiated cells have a
variable life span, which, depending on the tissue of origin, can range from a few days
to several months, see [32]. Artur Pappenheim was the first to formulate the concept
of stem cells for the hematopoietic system [90] and, years later, “hematopoietic stem
cells have been isolated from humans, and have been shown to be responsible for the
generation and regeneration of the blood-forming and immune systems” [97]. The
hematopoietic system (blood cell) system is depicted in Figure 1.1. Lung, breast,
prostate, and brain are additional instances of tissues for which the existence of
stem cells have been shown [8]. The cancer stem cell hypothesis thus assumes a
hierarchical structure in a tumor cell population. Because of this hierarchy, in a
tumor, CSCs would then be the real “engine” behind cancer progression [97, 8].
Where exactly cancer stem cells (CSCs) originate from is still unclear though: from
a healthy stem cell, which undergoes some harmful mutation, or from progenitor
cells that acquire self-renewal capacity or both [13]? There exists some evidence
that, at least in the case of CML, leukemic non-stem cells can acquire the ability to
undergo self-renewal [13, 93, 40]. Furthermore, it has been often assumed that the
slowly replicating CSCs would constitute only a very small fraction of the tumor
cell population [8, 13, 93, 97]. However there is recent experimental evidence that
CSCs may constitute a much larger proportion of a tumor [54, 94, 120, 114].
Aside the possible surgical removal of a tumor, chemotherapy is today one
of the most common treatments against cancer (radiotherapy and immunotherapy
being the other major ones). One of the main reasons for the failure of chemotherapy
3
Figure 1.1: The hematopoietic system. (Jeanne Kelly; commons.wikimedia.org).
is the development of drug resistance. In order to better address the issue of cell
resistance to anticancer drugs, we will briefly review what chemotherapy is, how it
has evolved in time, and how it works.
1.2 Chemotherapy
A chemotherapeutic drug is, broadly speaking, a chemical compound with the
ability to reduce the tumor load. At the end of the first millennium, Avicenna, an
Arab physician who pioneered experimental medicine and randomized clinical trials,
used arsenic compounds against cancer. While this procedure has been continuosly
used for centuries, the effects were not very encouraging. Approximately a century
ago, Paul Ehrlich coined the term chemotherapy to indicate a compound able to act
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as the “magic bullet” against infections [92].
The first modern chemotherapy drug used against cancer was discovered in
1942, when the US government asked two Yale assistant professors, L. S. Goodman
and A. Gilman, to study mustard gas, which had been developed and used as a
chemical warfare agent in World War I. The two researchers found that nitrogen
mustard, an alkylating agent derived from mustard gas, caused a dramatic regres-
sion of lymphoma in the patient under study. This discovery led in the late 1940s
and early 1950s to the investigation and subsequent use in clinical practice of var-
ious compounds: A. Haddow used urethane in CML patients, J. Burchenal used
methotrexate to treat leukemia in children, and S. Farber utilized aminopterin in
acute childhood leukemia [92, 32].
Since then, many more compounds have been found that are able of produc-
ing a significant regression of a tumor load. We can broadly divide the standard
chemotherapeutic agents as follows [106]:
1. alkylating agents (and variations): by attaching alkyl groups to the guanine
base of DNA double-helix strands, they chemically modify a cell’s DNA and
thus impair its function. Indeed by crosslinking guanine bases in DNA they
make the DNA strands unable to uncoil and separate. DNA replication is
impaired and therefore the cell can no longer divide.
2. antimetabolites: chemicals that are similar in structure to metabolites (molecules
that are part of the normal cell metabolism) prevent these substances from
being incorporated into the DNA during the S phase of the cell cycle (synthesis
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phase, when DNA replication occurs), consequently stopping normal cell de-
velopment and division by damaging the DNA strand. In fact antimetabolites
masquerade as purines or pyrimidines, molecules which are building blocks of
DNA.
3. plant alkaloids: by inhibiting the assembly of microtubules they block cell
division, due to the fundamental role played by microtubules in a cell.
4. topoisomerase inhibitors: by inhibiting topoisomerases, which are essential
enzymes that maintain the topology of DNA, they cause damages to the tran-
scription and replication of DNA (interfering with proper DNA supercoiling).
Importantly, these drugs do not differentiate between cancer and normal cells. How-
ever, given that cancer cells divide more often than normal cells, the inhibition of
cell division is expected to harm cancer cells more than healthy cells, since the afore-
mentioned drugs interfere with DNA replication or cell division. Unfortunately, a
general phenomenon for all such chemotherapeutic agents is that, aside from the
toxicity of the therapy, successive treatments will have decreasing therapeutic ben-
efits due to the development of resistance. Thus, while chemotherapy has proven
to be effective in the treatment of few types of cancer, such as lymphomas, germ
cell (sexual) and pediatric malignancies, in the majority of cases the results are
modest [116].
In the last decade new and less toxic drugs have been developed. These drugs
are known as “targeted therapies”. Instead of attacking both cancer and normal cells
without discrimination, the new drugs are specifically designed to target a particular
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molecular attribute (or mutation) that characterizes a given type of cancer. Imatinib
mesylate, for example, works by inhibiting the bcr-abl enzyme activity, which is
specific to CML (see [102, 19] and Chapter 6 of this dissertation for a more detailed
description). Because of the potential of these new therapies, we are witnessing the
rise of a new discipline, molecular oncology, whose focus is to understand the genetic
and biochemical mechanisms involved in cancer [116].
Nevertheless, even for these targeted therapies, the development of drug resis-
tance is still a fundamental problem. For example, mutations in the bcr-abl domain
will cause almost invariably resistance to imatinib for patients in advanced stages
of CML [68].
1.3 The biology of drug resistance
As already mentioned, drug resistance strongly limits the success of the therapy
and reduces survival rates. This is a fundamental problem since cancer that becomes
resistant to all available drugs may leave the patient with no therapeutic alternatives.
There are various classifications of drug resistance, which are briefly summarized
below. For a more comprehensive overview we refer to the book by Teicher [108]
and to the references therein.
Drug resistance may be permanent or temporary (in which case it can reverse
over time). Resistance is either relative or absolute, where relative resistance refers
to a resistance that depends on the dosage. Typically, in relative resistance, the
higher the dosage is, the smaller is the resistance that develops. On the other hand,
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in absolute resistance no matter what the dose is, a resistant cell will not be affected
by the drug. In general, contemporary literature seems to consider drug resistance
to be mainly relative rather than absolute (see, e.g., [24, 37, 79, 92]).
Drug resistance appears to be both a spontaneous phenomenon caused by
random genetic mutations, as well as an induced one (which means that patients
that take a particular drug increase the chances of developing resistance to it).
Indeed, there is clear experimental evidence that at least in the case of some drugs,
known as “mutagenic drugs”, the drug itself can induce resistance to itself (e.g.,
see [100, 101, 105]). Such resistance is referred to as “drug-induced resistance”.
Patient’s sensitivity to chemotherapy depends on many factors. We may divide
them into broadly two categories [108, 34]:
1. physiological resistance, which depends on host factors, like, for example, the
size, location, and growth rate of the cancer, the blood supply, the immune
system status, the tumor microenvironment, the tumor pH, or the patient’s
intolerance to the effects of a drug.
2. biological resistance, given by kinetic resistance or genetic and epigenetic al-
terations in the cancer cells.
In the following we will focus only on the second kind. “Kinetic resistance”
refers to the reduction in effectiveness of a drug which is caused by the cell division
cycle. Such resistance is generally only temporary. Many drugs (such as methotrex-
ate, vincristine, and citosine arabinoside, to name a few) are mainly effective during
only one specific phase of the cell cycle, e.g., during the S phase, when the DNA is
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synthesized. Thus, in the case of a short exposure to the drug, the cell will not be
affected if during that time it is in a different phase. Even more importantly, the
cell will be substantially invulnerable if it is out of the cell division cycle, i.e., in
a “resting state” or in the G0 state. This means that the number of cells that are
affected by the drug is lower for cell populations that have low proliferation rates.
Resistance to drugs may instead develop as a consequence of genetic events
such as mutations, rather than developing due to kinetic reasons. This category
includes both “point mutations” and “chromosomal mutations”, also known as “gene
amplifications”. Point mutations are random genetic changes that occur during cell
division. These mutations cause the replacement of a single base nucleotide or pair
with another nucleotide or pair in the DNA or RNA. This is a random event with
a very small (yet nonzero) probability that modifies the cellular phenotype, making
any of its daughter cells resistant to the drug. Other examples of genetic mutations
are frameshift and missense mutations. Gene amplification is the consequence of
an overproduction of a particular gene or genes. This means that a limited portion
of the genome is reproduced to a much greater extent than the replication of DNA
composing the remainder of the genome. Such a defect amplifies the phenotype
that the gene confers on the cell, which, in turn, induces resistance by essentially
providing the cells with more copies of a particular gene than the drug is able to
cope with. While gene amplification (and consequently the resistance induced by
it) may be a temporary phenomenon, point mutations are permanent.
The cause for genetic mutations is not completely clear. Is it a mainly ran-
dom phenomenon, or rather a drug-induced, directed one, perhaps both? Such a
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fundamental question has been the focus of the Nobel Prize winning work of Luria
and Delbrück [65]. Using fluctuation analysis, Luria and Delbrück showed that drug
resistance in in vitro bacterial cultures seems to have an important random compo-
nent. Many further in vitro experiments with tumor cell lines confirmed this result.
In vivo experiments have instead provided somewhat contradictory results [103, 32].
1.4 Structure of the dissertation
In this dissertation we consider the dynamics of drug resistance in cancer and
the related issue of the dynamics of cancer stem cells. We would like to note that
a fundamental consequence of the cancer stem cell hypothesis is that, in a tumor,
long-lived resistance to chemotherapy will only be caused by those cells that have
the ability of self-renewal, that is the cancer stem cells. Thus, if we assume such
hierarchy in the cancer cell population, for the problem of drug resistance we may
focus only on them. While there is a growing body of evidence on the existence and
role of CSCs, to date there is little data on the correctness of this assumption and its
clinical implications for therapeutic strategies [107, 13]. The rest of the dissertation
is organized as follows.
In Chapter 2 we review the existing mathematical modeling literature on can-
cer stem cells and drug resistance. Starting with chapter 3, we introduce new re-
search material.
In Chapter 3 we consider the question of the dependence - or not - of the
dynamics of drug resistance on the so called “turnover rate”, a variable which is an
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indicator of the relative frequency of cell division with respect to cell death. We
show how a very simple system of ordinary differential equations (ODEs) allows us
to obtain results comparable to those found in the literature with one important
difference. Indeed we show that the amount of resistance that is generated before
the beginning of the treatment, and which is present at some given time afterward,
always depends on the turnover rate, no matter how many drugs are used. Previous
work in the literature indicated no dependence on the turnover rate in the single
drug case while a strong dependence in the multi-drug case.
In Chapter 4 we develop a new methodology in order to derive an estimate of
the probability of developing resistance to drugs by the time a tumor is diagnosed.
Importantly, the heterogeneity of the cancer population is taken into account. More-
over, in the case of Chronic Myelogenous Leukemia (CML), we are able to infer the
preferred mode of division of the hematopoietic cancer stem cells, predicting a large
shift from asymmetric division to symmetric renewal.
In Chapter 5 we extend the results of Chapter 4 by relaxing the assumptions
on the average growth of the tumor, thus going beyond the standard exponential
case.
In Chapter 6 we briefly review the basic modeling assumptions and main
results found in the mathematical modeling literature on CML, and formulate a new
hypothesis on the effects that the drug Imatinib has on leukemic stem cells. Based
on this hypothesis, we then use our mathematical results to obtain new insights on
the dynamics of the development of drug resistance in CML.




In this chapter we review the existing literature on the mathematical modeling
of the cancer stem cell hypothesis and of drug resistance. We would like to comment
on some of the works and refer interested readers to the references therein. We
describe the main ideas of these models, the mathematical techniques involved and
their main results.
2.1 Models of the cancer stem cell hypothesis
While the first mathematical models of cancer were produced in the 1950s
by Nordling [81], Armitage and Doll [2], and Fisher [22], it was in 1963 that Till,
McCulloch and Siminovitch [109] proposed the first mathematical model of a cell
population growth where the stem cell hypothesis was included. In their model it is
assumed that a stem cell can either renew symmetrically, producing two daughter
stem cells, or differentiate symmetrically, producing two differentiated (not stem
cells) daughters. In this way the two division modes are simply equivalent to either
a stem cell birth or death, allowing the modeling of the cell population growth by
a birth and death process. Moreover the authors ran experiments on the growth of
spleen colony-forming cells, considered to be stem cells. After collecting the data,
they fit the stochastic model to the data, reaching the conclusion that the distri-
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bution of the number of spleen stem cells present in a growing colony of spleen
cells, after about ten days from the formation of the colony, was well approximated
by a gamma distribution. It is important however to note that the model assump-
tions leave out from the dynamics the fundamental case of an asymmetric division in
which a stem cell differentiates into one stem cell and one daughter cell (see Chapter
4). The model by Till, McCulloch and Siminovitch [109] was later used to describe
human cancer growth (see for example [66]).
Today there is a growing literature on mathematical models which incorporate
the cancer stem cell hypothesis among their assumptions and which are specific to
a given type of cancer. Examples include [73, 98, 23] for chronic myeloid leukemia,
which we will describe in detail in Chapter 6, [75, 51, 17, 52] for colorectal cancer,
and [21] for breast cancer. We would like now to briefly review the mathematical
models on colorectal and breast cancer mentioned above.
Michor et al. [75] study the colorectal tumorigenesis and whether chromoso-
mal instability (CIN), present in more than 80% of colorectal cancers and caused
by chromosomal mutations in certain genes, is an early occurring event driving tu-
morigenesis or rather a consequence of it. The cell population in the colonic crypt is
assumed to be hierarchical. A colonic stem cell is at the base of the crypt and divides
always asymmetrically producing one differentiated cell at the time, which enter in
a line that makes it slowly migrate to the top of the crypt where it will commit
apoptosis. Using numerical methods the authors estimate that even the presence
of very few genes subject to chromosomal mutations, will ensure that chromosomal
instability will emerge early in tumorigenesis.
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Johnston et al. [51] present a three compartment model for the colonic crypt to
account for stem cells, transit-amplifying, and fully differentiated cells. Both stem
cells and transit-amplifying cells are assumed to have the ability to self-renew and
differentiate. The dynamics of the tumor cell population is described by using a
system of three coupled ordinary differential equations with saturation terms. The
authors show that depending on the parameters, there are a series of stable equilibria
corresponding to benign stages of a tumor. Exponential growth will occur only
beyond certain parameters’ values. Furthermore such instability may be driven by
uncontrolled growth either in the stem cell compartment or in the transit-amplifying
cells. In [52] Johnston et al. consider in detail both cases and show that in both cases
it is possible to obtain any proportion of CSCs in a tumor under quite reasonable
assumptions. This conclusion is in contrast to the generally accepted view that
CSCs constitute only a small proportion of a tumor. We will see that this is also
one of our conclusions in Chapter 4 [114].
Also D’Onofrio et al. [17] assume three compartments in the intestinal crypt:
stem cells, semi-differentiated cells and fully differentiated cells. Both stem and
semi-differentiated cells are assumed to be able to self-renew and differentiate, while
fully differentiated cells no longer divide. A system of three difference equations is
used. Interestingly, nonlinearity is introduced into the model in one of two ways:
by considering random fluctuations in the parameters (where the parameters are
now stochastic processes) or by assuming that the respective probabilities to self-
renew, differentiate and commit apoptosis depend on the numbers of cells in each
compartment. The model is characterized by bifurcation between an increase in
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cell numbers leading to a stable equilibrium or to explosive exponential growth.
In addition, the authors show that tumor progression may be a consequence of
alterations in cell turnover or fluctuations in cell numbers, due to a normal event
like tissue damage.
Enderling et al. [21] formulate a mathematical model to describe the process of
mutations and stepwise development of breast cancer. They assume that the loss of
two tumor suppressor genes is sufficient to give rise to a cancer, where for each gene
two alleles are potential target for the first mutation in a gene compared to only one
for the second mutation. A system of ordinary and partial differential equations is
used where the effects of diffusion, random motility, and haptotaxis are included.
Using numerical simulations, it is shown that only the presence of a large number
of breast stem cells and tumor suppressor genes in the breast tissue can explain the
high incidence of breast cancer in women. Furthermore, the mathematical model
suggests that the most likely scenario is that the tumor arises from an area where a
mutation occurred in stem cells at an early age.
Finally, in Dingli et al. [15] a microenvironment composed by a small number
of stem cells (for example in the colonic crypt) is considered in order to study the
insurgence of a tumor among stem cells due to random mutations. All three modes of
stem cell divisions are considered while the number of stem cells is assumed to remain
constant over time. Thus, a Moran process is used to model the dynamics of the
stem cell population subject to mutations. Stochastic computer simulations show
that in order for CSCs to take over the normal stem cell population it is generally
required that the CSCs either have a fitness advantage or a higher probability to
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renew symmetrically when compared with healthy stem cells.
2.2 Mathematical models of drug resistance
Drug resistance has been extensively studied in the mathematical literature.
As already mentioned in Chapter 1, the modeling of resistance due to random point
mutations was motivated by the experimental findings of Luria and Delbrück [65] in
1943 on the development of resistance to antibiotics in bacteria due to mutations.
Using fluctuation analysis, the authors concluded that the development of resistance
is primarily a random phenomenon rather than a drug-induced, directed one. The
mathematical model the authors formulated in order to answer that fundamental
question was also important for the estimation of mutation rates. In the model, Luria
and Delbrück assume that the process starts with one normal cell and no mutants.
The occurrence of mutations is modeled by a random process, specifically a Poisson
process with an intensity function. Importantly, both normal and mutant cells are
assumed to grow deterministically in an exponential fashion. The probability of no
mutations is then calculated as well as the mean and the variance of the distribution
of the number of mutants [65]. Given these estimates it was possible to implement
methods for the estimation of mutations rates from the data. This Nobel Prize
winning work has been followed by a large literature on the study of the distribution
of the number of mutants in a population which grows exponentially, known as the
Luria and Delbrück distribution [121].
The first model of resistance to chemotherapy due to point mutations in cancer
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is the celebrated model by Goldie and Coldman and its extensions (see [10, 11, 29,
33, 30, 31, 32]).
In Goldie et al. [29] the growth of the drug sensitive cancer cell population is
approximated by using a deterministic exponential curve. At each division there is
a small positive probability that a cancer drug sensitive cell may give rise to one
drug resistant cancer cell daughter because of a random point mutation. Such a
mutant will generate a clone that grows according to a birth process. The number
of mutations occurring in the drug sensitive population up to a given time is instead
approximated by a Poisson distribution. It is also assumed that back mutations
cannot occur. The number of mutants present in the cancer cell population is then
given by a filtered Poisson process. The probability of having no resistant cells
present in a tumor is then calculated, where the nonexistence of resistant cells is
assumed to be the condition for being cured. We note that in the model by Goldie
and Coldman, the drug-sensitive population is modeled deterministically as in Luria
and Delbrück [65], but the drug resistant population is modeled stochastically rather
than deterministically. The main results of Goldie et al. [29] are that the probability
of having no drug resistance present in a tumor is inversely related to the tumor
size and that more frequent dosage repetitions are more successful in minimizing
the risk of drug resistance development than less frequent doses administered for a
longer period of time.
In Coldman et al. [33, 30] the authors extend the model to multi-drug resis-
tance. It is assumed that multiple drug resistance occurs in single steps where now
a cancer cell may be sensitive to all drugs, resistant to only one of the drugs, to two
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given drugs and so forth. The main conclusion of their study is that the best strat-
egy is to use all available drugs simultaneously. Furthermore, it is shown that, if the
simultaneous administration of all drugs is not possible, the sequential alternation
of all drugs is optimal when these drugs are equally effective.
Interestingly, Goldie and Coldman extended their mathematical model to con-
sider the development of drug resistance when the cancer stem cell hypothesis is
considered [31, 32]. Unfortunately, they assumed that a stem cell can either renew
symmetrically, producing two daughter stem cells, or differentiate symmetrically,
producing two differentiated (not stem cells) daughters. In this way the two divi-
sion modes are simply equivalent to either a stem cell birth or death, leaving out
from the stem cell dynamics the fundamental case of an asymmetric division, where
a stem cell and a differentiated daughter cell are produced. The model then reduces
to the usual birth and death process of a growing population.
A more recent study on point mutations is by Komarova et al. [60, 58, 61, 59].
For example, in [60, 58], a model which is based on stochastic birth and death pro-
cesses on a combinatorial mutation network is used to describe the development
of resistance to multi-drug treatments. Thus, probabilistic methods and a hyper-
bolic PDE are used to show how the pre-treatment phase is more significant in the
development of drug resistance than the treatment phase. This is a very natural, in-
tuitive result given that the treatment will, in general, drastically reduce the cancer
population and consequently also reduce the number of possible cell divisions and
mutations. Moreover, the main result obtained in [58, 60] is the following: in the
case of a single drug treatment, the probability to have resistant mutants generated
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before the beginning of the treatment and present, including their progeny, at some
given time afterward, does not depend on the cancer turnover rate. A consequence
of such result is that also the probability of treatment success does not depend on
such a rate. For the case of a multi-drug treatment, instead, in [58] it is shown
that the probability of having resistant mutants strongly depends on the turnover
rate, and, therefore, the probability of treatment success also will strongly depend
on this rate. One of the goals of Chapter 3 is to understand the reason for such a
difference between the single and multi-drug cases. In Komarova et al. [60, 59] the
same methodology is used to analyze the development of resistance in CML. In [60]
it is suggested that a combination of three drugs with different specificities might
overcome the problem of resistance. In Komarova et al. [59] it is observed that
combining more than two current drugs will not provide any further therapeutic
advantage, due to the problem of cross-resistance.
Another recent work on point mutations is by Iwasa et al., [50], in which
continuous-time branching processes are used to calculate the probability of resis-
tance at the time of detection of the cancer, as well as the expected number of
mutants found at detection if resistance developed. These estimates are found both
for the case where drug sensitive and drug resistant cells have the same birth and
death rates as well as for the cases where the drug resistant cells have a fitness
advantage or disadvantage with respect to the wild-type cancer cells. Similarly to
the results of [29], the authors of [50] show that the probability of resistance is an
increasing function of the detection size and the mutation rate. In a later paper [39]
the model is extended to obtain the same estimates for the case of a two-drug treat-
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ment. We refer to Chapter 4 for further details.
We will not consider in the next chapters the modeling of drug resistance due
to gene amplification, kinetic resistance or drug induced resistance. We would like
to comment on some of the works on these types of resistance and refer interested
readers to the references therein.
Modeling of resistance due to gene amplification can be found, e.g., in [42, 43,
56]. Drug resistance in these works is studied using stochastic branching models.
Kinetic resistance has been mathematically studied in [4] and [89]. The models in
these papers are based on ODEs. An alternative approach on kinetic resistance,
using age-structured models, can be found in [9, 14, 25, 26, 117]. Finally, for mathe-
matical models and experimental findings on drug-induced resistance, we refer, e.g.,
to [36, 105, 88].
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Chapter 3
The Dependence of Drug Resistance on the Turnover Rate
3.1 Introduction
In this chapter we introduce a very simple model for absolute drug resistance,
which we assume is caused only by random genetic point mutations. For this par-
ticular setup, most existing mathematical models are based on stochastic methods.
In contrast, our approach is based on a compartmental system of ODEs, whose vari-
ables are the normal cancer cell population (that is susceptible to the drug), and
the population of cancer cells that are resistant to the drug due to point mutations.
The purpose of this model is to show that elementary ODE-based techniques
can be successfully used to obtain comparable results to those that were previously
derived using the more complex mathematical machinery of stochastic methods.
The structure of the chapter is as follows: In Section 3.2, we outline the basic
modeling assumptions and develop our mathematical model of drug resistance. We
start by considering the single drug case, and proceed with the more general case of
two or more drugs. The main results that we obtain from the model are presented in
Section 3.3. We show that the amount of resistance generated before the beginning
of the treatment, and present at some given time afterward, always depends on the
turnover rate, no matter how many drugs are used simultaneously. We also use
our model to compare the amount of resistance that originates before and after the
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treatment starts. Section 3.4 focuses on studying the differences between our results
and other works in the field. Concluding remarks are provided in Section 3.5.
Once again we would like to stress that the main contribution of this chapter
is in providing an elementary way to derive comparable results to those that were
previously obtained using substantially more complex mathematical machinery. The
content of this chapter has been published in [112, 113].
3.2 An elementary model for drug resistance
In this section we develop a simple mathematical model for absolute drug
resistance in the presence of random genetic point mutations. Our approach is to
model the process using a linear system of ODEs. In its essence, our model enjoys
similarities with the well known model of Goldie and Coldman [30] (see also [25]).
The main difference between our approach and [30], is that we do not make any
use of probability theory. Instead, we rely on a purely deterministic system. The
advantages and disadvantages of using such an approach will be examined below.
3.2.1 The single-drug case
We start with the case of resistance to a single drug. Accordingly, we follow
two populations: The first group is composed of wild-type cancer cells (cells that
are sensitive to the drug). We denote the number of wild-type cancer cells at time
t, by N(t). The second group are cells that have undergone a mutation. These cells
are resistant to the drug. The number of mutated cells at time t is denoted by R(t).
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We assume that cancer grows exponentially according to the Skipper–Schabel–
Wilcox model, also known as the log kill model (see [104]). We also assume that the
drug therapy starts at t∗. Our model can then be written as:
N ′(t) = (L−D)N(t),
R′(t) = (L−D)R(t) + uN(t).
t ≤ t∗. (3.1)

N ′(t) = (L−D −H)N(t),
R′(t) = (L−D)R(t) + uN(t).
t > t∗. (3.2)
The system (3.1) describes the pre-treatment phase, while the system (3.2) follows
the dynamics after the treatment starts. The difference between both systems is
the introduction of H, the drug-induced death rate, a term that appears only after
the treatment starts, i.e., in (3.2). In both systems, L, D, and u denote the birth,
death, and mutation rates, respectively. We assume that 0 ≤ D < L and 0 < u 1.
The system (3.1) is written assuming that mutations occur as a result of a wild-
type cell differentiating into one wild-type and one mutant cell. This is a standard
assumption, see, e.g., [58].
The initial conditions for the pre-treatment system (3.1) are given as constants
N(0) = N0 6= 0 and R(0) = 0. The initial conditions for the system (3.2) are N(t∗)
and R(t∗), which are the solutions of (3.1) at t = t∗.
Remarks:
1. In this model we assume that both the wild-type and the resistant (mutated)
cells have the same birth and death rates. This assumption is made in order
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to simplify the initial presentation, and can be easily modified to model situ-
ations where the resistant cancer cells R have a relative fitness advantage or
disadvantage with respect to the wild-type cancer cells N . Indeed it is increas-
ingly recognized that resistance to chemotherapy comes at a fitness cost, see
for example [27]. If we consider the more general case where different birth
and death rates are assumed for the wild-type and the mutated cells, in the
single-drug case the model becomes:
N ′(t) = (L−D)N(t),
R′(t) = (L̃− D̃)R(t) + uN(t).
t ≤ t∗. (3.3)

N ′(t) = (L−D −H)N(t),
R′(t) = (L̃− D̃)R(t) + uN(t).
t > t∗. (3.4)
We assume that (L̃ − D̃) 6= (L − D), given that otherwise we are back to
system (3.1).
2. Another modification could be to replace the exponential growth of cancer
by a different model such as the gompertzian growth, which was empirically
shown to provide a better fit (see the Norton-Simon hypothesis in [83], [82],
[84]).
3. We assume that mutations happen only in one direction, i.e., wild-type cells
mutate and become resistant but not vice versa. This seems to be a reasonable
assumption in the case in which the focus is on point mutation resistance and
not on resistance caused by gene amplification. Indeed, the probability of
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reversal of a point mutation is much smaller than the probability of the point
mutation itself, and can therefore be neglected (see [18, 73, 50, 58]).
4. The time of the beginning of the treatment, t∗, can be related to the size of
the tumor at that time. If we assume that the total number of cancer cells at
time t∗ is M , we can use the exponential growth of cancer and the relatively







3.2.2 The 2-drug case
We now consider the case of a treatment in which two drugs are being simul-
taneously used. We denote by R1(t) and R2(t), the mutant cancer cell populations
that mutated by time t so that they are resistant only to the first or to the second
drug, respectively. We reserve the notation R(t) for the population of cells that
are resistant to both drugs at time t. With these notations, the model for drug
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resistance with two drugs can be written as:
N ′(t) = (L−D)N(t),
R′1(t) = (L−D)R1(t) + uN(t),
R′2(t) = (L−D)R2(t) + uN(t),
R′(t) = (L−D)R(t) + uR1(t) + uR2(t).
t ≤ t∗. (3.6)

N ′(t) = (L−D −H)N(t),
R′1(t) = (L−D −H)R1(t) + uN(t),
R′2(t) = (L−D −H)R2(t) + uN(t),
R′(t) = (L−D)R(t) + uR1(t) + uR2(t).
t > t∗. (3.7)
Similarly to the single-drug case, also in the 2-drug case we distinguish between the
pre-treatment dynamics (described by (3.6)) and the dynamics after the treatment
started, which is given by (3.7).
Remarks:
1. Note that we assume that if a cell is already resistant to one drug it does
not make it any less vulnerable to the combination of drugs (i.e., H remains
unchanged). Such an assumption can be justified given that for cells that are
resistant only to one drug, the second drug is still effective. This assumption
can be easily modified to account for matters of physical or chemical nature
that can influence the level of resistance that a cell (that is already resistant
to one drug) may develop to the second drug.
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2. We assume that the probability of a point mutation, and consequently the
mutation rate u, is the same for any non fully resistant state in which a cell
may be, an assumption that can also be easily modified.
3.2.3 The n-drug case
Extending the 2-drug model (3.6)–(3.7) to the setup of n drugs is straightfor-
ward. The resulting general n-drug case (with n ≥ 1) is as follows. The system for
the pre-treatment phase (t ≤ t∗) is:
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N ′(t) = (L−D)N(t),
R′1(t) = (L−D)R1(t) + uN(t),
...
R′n(t) = (L−D)Rn(t) + uN(t),
R′1,2(t) = (L−D)R1,2(t) + uR1(t) + uR2(t),
...
R′1,n(t) = (L−D)R1,n(t) + uR1(t) + uRn(t),
R′2,3(t) = (L−D)R2,3(t) + uR2(t) + uR3(t),
...
R′2,n(t) = (L−D)R2,n(t) + uR2(t) + uRn(t),
...
R′1,...,n−1(t) = (L−D)R1,...,n−1(t) + u
∑n−1
i=1 R(1,...,n−1)\i(t),




R′1,...,n−2,n(t) = (L−D)R1,...,n−2,n(t) + u
∑n
i=1,i 6=(n−1)R(1,...,n−2,n)\i(t),





The system that describes the dynamics during the treatment (t > t∗) is:
N ′(t) = (L−D −H)N(t),
R′1(t) = (L−D −H)R1(t) + uN(t),
...
R′n(t) = (L−D −H)Rn(t) + uN(t),
R′1,2(t) = (L−D −H)R1,2(t) + uR1(t) + uR2(t),
...
R′1,n(t) = (L−D −H)R1,n(t) + uR1(t) + uRn(t),
R′2,3(t) = (L−D −H)R2,3(t) + uR2(t) + uR3(t),
...
R′2,n(t) = (L−D −H)R2,n(t) + uR2(t) + uRn(t),
...
R′1,...,n−1(t) = (L−D −H)R1,...,n−1(t) + u
∑n−1
i=1 R(1,...,n−1)\i(t),




R′1,...,n−2,n(t) = (L−D −H)R1,...,n−2,n(t) + u
∑n
i=1,i 6=(n−1)R(1,...,n−2,n)\i(t),




In these equations we used the obvious extension of the notation. For example,
R(1,...,n)\i denotes the mutant cancer cell population that is resistant to all drugs
with the exception of drug #i.
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3.3 Analysis and results
In this section we discuss the main results that can be obtained by analyzing
the models for drug resistance that were introduced in Section 3.2.
3.3.1 Dependence on the turnover rate D/L
Our first result is that the amount of resistance present at the time when the
treatment starts, t∗, always depends on the turnover rate D/L no matter how many
drugs are simultaneously used. This result is easily obtained by considering the
solutions of R(t∗) in the single-drug systems (3.1), the two-drug system (3.6), and
the n-drug system (3.8). We briefly outline the derivation of the solutions (3.10) and
(3.12). By writing the ODE system (3.1) in matrix form, we obtain the following
matrix: L−D 0
u L−D




where I is the identity matrix. The last matrix is nilpotent of order 2, thus the









∗ ≈ Mu ln(M/N0)
L(1−D/L)
, (3.10)
where M is the total number of cancer cells when the therapy begins. In the more
general case where different birth and death rates are assumed for the wild-type and
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Similarly, by writing the ODE system (3.6) in matrix form, we obtain the
following matrix:
L−D 0 0 0
u L−D 0 0
u 0 L−D 0




0 0 0 0
u 0 0 0
u 0 0 0
0 u u 0

.
The last matrix is nilpotent of order 3, thus the fundamental matrix is given by
e(L−D)t

1 0 0 0
ut 1 0 0
ut 0 1 0
(ut)2 ut ut 1

,


















The various expressions for R(t∗), (3.10)–(3.13), contain the turnover ratio D/L.
We can thus conclude that the slower the growth of the cancer is (i.e., the closer
the turnover rate D/L is to 1) the larger is the pre-treatment drug resistance.
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Conversely, the faster the tumor grows (i.e., the closer the turnover rate is to zero)
the smaller is the resistance that develops prior to the beginning of the treatment.
This result is independent of the number of drugs.
3.3.2 How much resistance originates before the treatment?
Assume that mutations could be terminated after time t∗ so that the only
drug resistance that is present after t∗ would be the “progeny” of the resistance
generated before therapy started. We refer to such resistance as the “pre-treatment
resistance at time t” and denote it by Rp(t). We would like to compare Rp(t) with the
resistance that is generated exclusively by mutations that occur during treatment,
which we denote by Rd(t), and refer to as the “during-treatment resistance at time
t”. Mathematically we can stop the mutations by setting u = 0.
Our second result is that for any t > t∗, the pre-treatment resistance is greater
than the during-treatment resistance, i.e., Rp(t) ≥ Rd(t). This result holds under
the assumptions that (L−D) < H and M/N0 ≥ C, where the constant C depends
on the number of drugs. For example we will see that in the one-drug case, C = e,
and in the two-drug case C = exp(1 +
√
(3)).
Indeed, in the single drug case, the solution of the system (3.2), subject to the




[e(L−D)t − e(L−D−H)t]. (3.14)
Here, to simplify the notations, time is measured from the beginning of the treat-
ment, i.e., t = 0 refers to what we previously considered to be t = t∗.
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On the other hand, Rp(t) is the solution of (3.1) at time t∗ that is then multi-













which nicely illustrate the key players in determining the proportion between the two
populations. We would like to stress that in the case of mutagenic drugs, where the
mutation rates are much higher during treatment, the result may be easily reversed,
i.e., the resistance generated after the beginning of the treatment may exceed the
pre-treatment resistance.


























Similarly to the single drug case, Rp(t) is the solution of (3.6) multiplied by the


















which is impossible given the assumptions.
Remarks:
1. A similar result can be obtained in the n-drugs case. Rp(t) is the solution of
(3.8) multiplied by the exponential term e(L−D)t to account for the growth of






















































2. Equations (3.15), (3.18) and (3.19) clearly show how the amount of resistance
generated before the beginning of the treatment and present, including its
progeny, at any given time afterward depends on the turnover rate.
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3. We note that in the two-drug case, the interval in which the pre-treatment
resistance is smaller than the during-treatment resistance, i.e., Rp(t) < Rd(t),
is slightly larger than in the single drug case.
4. If we allow the drug-induced death rate to take different values, for example,
H/2 for the populations R1 and R2 and H for the population N , (which models
a situation in which only one of the two drugs can kill these cells), then the
interval for which Rp(t) < Rd(t) can be made larger. For the particular choice










The discussion in this section is devoted to comparing the results obtained with
our model and the results obtained in [50, 60, 58]. One of our motivations is indeed
to understand the main result obtained in [58, 60], which is the following. In the
case of a single drug treatment, the probability to have resistant mutants generated
before the beginning of the treatment and present, including their progeny, at some
given time afterward, does not depend on the cancer turnover rate. A consequence
of such result is that also the probability of treatment success will not depend on
such rate. For the case of a multi-drug treatment, instead, in [58] it is shown
how there appears to be a strong dependence of the probability to have resistant
mutants on the turnover rate, and therefore also the probability of treatment success
will strongly depend on such rate. Our goal is to understand the reason for such a
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difference between the single and multi-drug cases. This is accomplished by using
our different, simpler approach.
The problem studied in all papers is similar, i.e., drug resistance caused by
random mutations, though the mathematical techniques being used are different.
Here we use a deterministic system of ODEs as opposed to the various stochastic
methods used in [50, 60, 58]. The specific goals of each paper are somewhat different.
In [50] the probability to have developed resistance by the time of clinical detection
of the cancer is calculated. Instead, in [60, 58] the focus is on the probability to
have resistance as t→∞. Finally, in our paper we calculate the “average” amount
of resistance developed at any given time before and after the beginning of the
treatment. We would like to note that while in this work we deal with numbers of
cells, in [50, 60, 58] the quantities of interest are probabilities.
Comparing our results with some of the main results of [50, 60, 58], the outcome
is as follows:
1. Our results agree with [50], in the sense that both works clearly show the
dependence of resistance on the turnover rate at the time of detection (see
equation (3.15) and table 1 of [50, page 2563], also found below as equation
(3.21)). Furthermore, our results agree with [50] also on the effect that the
mutation rate and the detection size have on resistance.
2. Most of our results agree with the results of [58, 60] which are summarized on
page 352 of [58]. For example, in [58] it is shown that the pre-treatment phase
is more significant in the development of resistance than the treatment phase.
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This is a very natural, intuitive result given that the treatment will in general
drastically reduce the cancer population, and therefore also the number of
possible cell divisions and mutations. With our model such result was easily
obtained. However there is one important difference between our results and
those found in [58]. In our work, we show that no matter how many drugs
are used in the treatment, the amount of fully resistant mutants (generated
before the beginning of the treatment and present, including their progeny, at
some given time afterward) depends on the turnover rate. See (3.10)–(3.13)
and Remark 2 in Section 3.3. In contrast, one of the main results of [58, 60]
was that this dependence holds only in the multi-drug setup, and not for the
single drug case (see [58, page 360]). The reason for this difference is due
to the fact that [58] studies the probability to have such resistance in the
limit, as t → ∞. It is only at t = ∞ that the results of [58] show a lack of
dependence of the resistance on the turnover rate (see page 365, equation (49)
and the following discussion in [58]). This result does not hold at any finite
time. This result can be further understood by the following argument. Using
mixed techniques of ordinary differential equations and branching processes it
is possible to calculate - as we will see in chapter 4 - the probability to have
resistant mutants generated before the beginning of the treatment and present,
including their progeny, at some given time afterward. This probability is given
by the following formula











Here the time t is measured from the start of the treatment. Once again
it is clear that this probability given by (3.20) does depend on the cancer
turnover rate for any finite time t . The asymptotic analysis found in [58]
loses this information, indeed it is only asymptotically that such dependence
will disappear. Clearly, the strength of such dependence will depend on the
actual values of the parameters.
Furthermore, the conclusion in [58] that in the single drug case, the probability
of treatment success does not depend on the turnover rate (see [58, page 352]),
is related to the definition of a successful treatment as a complete extinction
of the tumor as time becomes infinite. Different definitions of a successful
treatment (such as allowing tumors not to exceed a certain size or simply
considering finite times) will lead to a dependence on the turnover rate also in
the single drug case.
3. The elementary mathematical tools that we used in formulating our model,
enable us to analytically study the n-drug case. Of course, with an increasing
number of drugs, any deterministic model that considers averaged quantities
has a limited validity. For two drugs or more, the results obtained using the
approach in [60, 58] rely on numerical simulations.
4. Due to the simplicity of our model is it easy to consider the dynamics of
resistance also in the more realistic case of treatment regimes where the drugs
are administered intermittently. In such a scenario, one interesting issue is
to study the connection between the frequency of the administration of the
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drug (e.g. when the total dosage is fixed) and the development of resistance.
It is also straightforward to compare different therapy regimes. Such a study
would be particularly interesting if we assume a different model for the cancer
growth. This setup is beyond the scope of this paper and it is left for future
research.
5. Since our approach is deterministic, it has a definite disadvantage when com-
pared with stochastic models as it does not provide the time-dynamics of the
probability distribution of the generated resistance. At the same time, it is
important to note that the stochastic approach may yield results of a limited
value. Indeed, according to [50], the probability that resistance develops by
the time of detection in the one-drug case is given by









Here, M is the detection size. Hence, for values of M = 109 (which, at
present, is approximately the lower limit of clinical detection, see [92, page
31]) and u ≥ 10−8 [63, 73, 111], the probability that resistance develops by
the time a tumor is detected is always greater than .9999. This is the case
since (L/D) ln(L/(L −D)) is always greater than 1 if D < L, where the last
inequality is supported by experimental data [110]. Hence, in this case the
actual calculation of the probability distribution of the generated resistance,
while showing the explicit dependence on the parameters, may not provide
useful information if the product of M and u is greater than 1.
6. While from a mathematical point of view, it is a common practice to compute
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asymptotics as t → ∞, it is more desirable in the problem of drug resistance
(and its related concept of treatment success) to study the dynamics for finite
time, a time that is at most of the order of several years.
Importantly, we would like to note that also the results found in Michor et
al. [73] (see also [99]), which are supported by clinical data, indicate the dependance
of drug resistance on the cancer turnover rate.
3.5 Conclusion
In this chapter we developed a simple compartmental ODE model for absolute
drug resistance, which is assumed to be caused only by random genetic point muta-
tions. Our model was derived and analyzed for an arbitrary number of drugs. The
simplicity of our model is the main strength of our approach. Alternative approaches
to the problem that are based on stochastic methods, become very complex with
an increasing number of drugs. Of course, with an increasing number of drugs, any
deterministic model that considers averaged quantities has a limited validity.
One of our goals was to understand the reasons behind the difference in the
results of Komarova [58] for the single and multi-drug cases. We have shown that
the amount of resistance that is generated before the beginning of the treatment,
and which is present at some given time afterward, always depends on the turnover
rate, no matter how many drugs are used. The dependence on the turnover rate in
the single drug case is simply weaker that the dependence in the multi-drug case.
This result contradicts some results in the literature, as discussed in Section 3.4.
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Additional results that were obtained with our model, validate the correspond-
ing results in the literature. In particular, we demonstrate that, with the reasonable
biological assumptions L − D − H < 0 and M/N0 > C (see [58]), the resistance
whose origin is before treatment is greater than the resistance created after the
therapy starts, at any given point in time. Note that a violation of the first assump-
tion would imply that the therapy is not able to reduce the size of the tumor, even
without any resistance being present.
In conclusion, we consider the modeling via a system of ODEs to be a simpler
and at least in some sense a better way to approach the problem of acquired drug
resistance, especially if the focus of the analysis is on the dynamics following the
time of the tumor’s detection. Due to the simplicity of our approach, it is possible to




The Role of Symmetric and Asymmetric Division of Stem Cells
4.1 Introduction
In this chapter, we will focus only on resistance due to genetic mutations and,
due to the results of Luria and Delbrück, we will assume that such resistance is
caused by a random mutation mechanism. Furthermore, we will consider the case
of absolute resistance, i.e., resistance that is not relative to the dosage of the drug
administered. A cancer cell is either resistant to the drug or not, once the dosage
of the drug is prescribed.
In a recent work [50], Iwasa et al. have shown that the probability that
resistance to a drug develops by the detection time is given by









Here, M is the total number of cancer cells found at detection; u the probability of
mutation per cell division; and L and D are the birth and death rates, respectively.
This result was obtained using Markov chains and continuous time branching pro-
cesses. Furthermore, in the case where Mu  1, the expected number of resistant
cancer cells found at detection, conditional on the presence of resistance, is
Ȳ ≈ lnM
(L/D − 1) ln (L/(L−D))
. (4.2)
It is important to emphasize that the study in [50] is based on assuming that
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cancer cells are a homogeneous population, which is why M is taken to be the total
number of cells. Yet, recent experimental evidence suggests that tumors should
not be thought of as homogeneous. Indeed, it appears that tissues are maintained
by a small subset of slowly replicating cells. These so-called “stem cells” have the
capacity of both self-renewal and differentiation into more mature cells. Stem cells
are very long lived, while mature, fully differentiated cells have a variable life span,
which, depending on the tissue of origin, can typically range from a few days to
several months.
From the point of view of drug resistance, the heterogeneity hypothesis im-
plies that only the cells that have the capacity for self-renewal can propagate drug
resistance. Therefore, these cells should be taken into account in any model of drug
resistance in cancer. In fact, these are the only cells that should be taken into
account.
The rest of the chapter is devoted to deriving, presenting, and applying the re-
sults we obtained while calculating the probability of developing resistance to drugs
by the time a tumor is diagnosed, this time taking into account the heterogeneity
of the population.
To demonstrate the significance of our result, we focus on chronic myeloid
leukemia (CML) for which a recent study has been published on a six-year follow up
of patients that receive imatinib as the first line of treatment [45]. The clinical study
provides us with a concrete estimate of the percentage of patients that shift from the
chronic phase to the acute phase (or enter into a blast crisis). We use this estimate as
an upper bound on the number of patients that have developed resistance to the drug
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by the time CML was diagnosed. By integrating the mathematical estimates with
clinical and experimental data, we are able to infer the preferred mode of division
of the hematopoietic cancer stem cells, predicting a large shift from asymmetric
division to symmetric renewal. Such a shift is required in order to explain the
clinical data. The content of this chapter has been published in [114].
4.2 Model derivation
We derive the mathematical model using ordinary differential equations for
the wild-type cancer population and branching processes for the mutant cells. In
Iwasa et al. [50] both the wild-type and the mutant cancer populations are modeled
as stochastic processes. Our deterministic approach in modeling the total number of
drug-sensitive cancer stem cells (CSCs) is equivalent to considering their averaged
behavior. For completeness we derive in Section 4.2.6 the corresponding model
in which both populations are represented by branching processes. The standard
theory for these multi-type branching processes can be found in [3, 56] and especially
in the book by Mode [76]. As we will show, however, this approach does not allow
to obtain completely satisfactory results. Thus the methodology we used in the
paper may be seen as a more satisfactory approach with respect to the standard
multi-type branching processes approach. Moreover our methodology appears to be
a simplified version of the stochastic approach taken by [50, 20] and in this sense
it has the advantage of easily allowing modifications. For example, an exponential
cancer growth may be a good assumption only when the cancer population is small.
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To replace it by any other growth model, while straightforward with the ODEs
approach, would be a somewhat more complex undertaking when dealing directly
with stochastic methods. Furthermore, we would like to note that arguably our
modeling methodology may be seen as more general, in the sense that at least for
the wild-type population we only make assumptions on their averaged behavior (no
Markov property for example). Finally, we note that if the cells are assumed to be a
homogeneous population then our results, obtained through a partially deterministic
methodology, match exactly the results of Durrett et al. obtained by the completely
stochastic approach [20].
4.2.1 Ordinary differential equations
We assume that a stem cell may divide in the following three ways (shown in
Figure 4.1):
1. asymmetric division: a stem cell divides into one progenitor cell and one
stem cell;
2. symmetric differentiation: a stem cell divides into two progenitor cells;
3. symmetric renewal: a stem cell divides into two stem cells.
All three types of division have been observed experimentally (see [78, 87, 118,
69, 119]). We can therefore assign probabilities to the three division paths of stem
cells as follows: we denote by a the probability of an asymmetric division, by b the
probability of a symmetric differentiation, and by c = 1− a− b the probability of a
faithful symmetric renewal. Clearly, 0 6 a, b, c 6 1 and a+ b+ c = 1.
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Figure 4.1: The different ways in which a stem cell may divide: (1)
asymmetric division in which a stem cell divides into one progenitor cell
and one stem cell; (2) symmetric differentiation in which a stem cell
divides into two progenitor cells; and (3) symmetric renewal in which a
stem cell divides into two stem cells.
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Since we are interested in the dynamics of drug resistance in cancer, we will
focus from now on on cancer stem cells. In addition we focus on the case of a single
drug therapy. We denote the total number of wild-type, i.e., drug-sensitive cancer
stem cells at time t by S(t). This population is assumed to grow exponentially. The
second group of cells, the mutated cancer stem cells that developed resistance to
the drug are denoted by R(t). The dynamics of the averaged behavior of the two
cell populations can be described using the following system:
S ′(t) =
[















We assume that at time t = 0, we start with a single wild-type cancer stem
cell, and no mutated stem cells. Consequently, the initial conditions for (4.3) are
given by S(0) = 1 and R(0) = 0. As previously stated, u is the mutation probability
per cell division, while L and D are the birth and death rates, respectively. To be
precise, from now on, we will refer to L as the division rate, since a division may
not result in the birth of a stem cell. In addition, since the mutation probability
is usually extremely small, the system (4.3) is written under the assumption that
mutations may occur in the division process only to one of the two daughter cells.
This is a standard assumption, see e.g. [60, 50].
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In the first equation in (4.3), the size of the wild-type cell population can
increase only as a result of a symmetric renewal, were no mutation occurs. The
probability of such an event is (1 − u)(1 − a − b). Multiplying this probability by
the division rate L provides the birth rate of S(t). On the other hand, a decrease
in the wild-type population will occur in the following cases: a cell death (D), a
symmetric differentiation into two progenitors (bL), and if there is an asymmetric
division (aL) in which the stem cell daughter is the mutant. The stem cell daughter
will be the mutant with probability u/2, since u is the probability of mutations, and
in this scenario only one of the two daughter cells is a stem cell.
For the second equation in (4.3), the size of the mutant population can once
again increase only due to a symmetric renewal. Only that this time, we assume
that mutated cells can no longer mutate back to the wild-type state (due the rarity
of this event for point mutations). A decrease in the mutant population will be the
result of cell death and of a symmetric differentiation into two progenitors. The
last term of the equation are the wild-type cells that mutated. They either come
from a symmetric renewal: uL(1− a− b), or from an asymmetric division in which
a mutation hits the daughter stem cell: uLa/2. The sum of these two terms is
uL(1− a/2− b).
Given that u is very small, it can be eliminated from the first equation. How-
ever, it cannot be removed from the second equation since S(t) is much larger than
R(t). The system (4.3) can be thus reduced to the following:
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S ′(t) = [L(1− a− 2b)−D]S(t),








We would like to make the following remarks.
1. Since we are modeling a cancer stem cell population that is assumed to grow
from one cell to a large number, it must be that [L(1−a−2b)−D] > 0, which
implies that (1− a− 2b) > 0 and therefore (1− a
2
− b) > 0.
2. Since the mutant population is always considered to be very small, we are
actually not going to use the equation for R(t) from (4.4). This equation
will be replaced with a stochastic approach. It is still instructive to keep this
equation as part of the system (4.4) since it can be used to understand the
meaning of the final formulas.
3. In this model we assume that both the wild-type and the resistant stem cells
have the same division and death rates and the same division events probabil-
ities a, b. This assumption is made in order to simplify the presentation, and
can be easily modified to model situations where the mutant cancer cells R(t)
have a relative fitness advantage or disadvantage with respect to the wild-type
cancer cells S(t) (as done in [50]).
4. Due to the simplicity of our approach, the assumption regarding the exponen-
tial growth of cancer can be easily replaced by any other growth model. Such a
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modification is more complex when dealing directly with stochastic methods.
5. We assume that mutations happen only in one direction, i.e., wild-type cells
mutate and become resistant but not vice versa, and thus (1−u) is not multi-
plying L in the second equation. This seems to be a reasonable assumption in
the case in which the focus is on point mutation resistance and not on resis-
tance that is caused by gene amplification. Indeed, the probability of reversal
of a point mutation is much smaller than the probability of the point mutation
itself, and can therefore be neglected.
6. By modeling the cancer stem cell population growth in a deterministic way
instead of as a random process, we lose the sensitivity to events that can
happen for small populations, such as a population going extinct. Our focus
in this study is on modeling the case where the wild-type cancer stem cell
population reaches a detection size, M , and on its impact on drug resistance.
Such a deterministic approach cannot provide the probability distribution of
how long it takes for the tumor to reach detection size. However, our study
provides the average behavior of such time. Interestingly, the formulas that
we obtain using our mixed approach, are in exact agreement with the results
that were derived with the full-blown stochastic approach (in the simple case
where only symmetric renewal is considered, the only case that was previously
studied with stochastic methods [50]).
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4.2.2 The expected number of mutations when the size of the wild-
type population is x
At this stage we can use the system (4.4) to estimate the expected number of
mutations, mx, that occur once the wild-type population is of size x.
Consider the first equation of system (4.4). As first step, we are interested in
finding the expected lengths of time for which the total number of wild-type cancer
stem cells S(t) is equal to 1, 2, . . . ,M − 1. Here, M is the number of wild-type
cancer stem cells at detection time. Note that, given the very small probability of a
mutation, M is also a good approximation of the total number of cancer stem cells
found at detection, i.e. both wild-type and mutated ones. Since the solution of (4.4)
for S(t) is given by
S(t) = exp[(L(1− a− 2b)−D)t], (4.5)
then the “average” time at which the wild-type cancer stem cell population reaches





Thus the “average” length of time for which the population will consist of exactly
x stem cells is







Hence, the “expected number” of mutations occurring when there are exactly x










This expression is obtained by multiplying the number of wild-type stem cells present
at that time, x, by the mutation rate uL(1 − a
2
− b), and by the length of time for
which the total stem cell population equals x.
Finally, note that ϕ := x ln(1+1/x) ∼ 1, (e.g., ϕ ≈ .9 for x = 4 and ϕ ≈ .98 for
x = 20). Hence, since we are ultimately interested in large values of x, equation (4.8)










Note that if the cancer stem cell population is growing, L(1− a− 2b)−D must be
greater than zero and hence the expression in (4.9) is well defined.
4.2.3 Branching processes
We are ultimately interested in calculating the probability of developing drug
resistance by the time a tumor is detected. At this stage of the analysis, it is proper
to take advantage of stochastic methods.
Assume that the tumor population grows exponentially starting from one wild-
type stem cell. Let rx be the actual number of mutations produced when there
are x = 1, 2, . . . ,M − 1 wild-type cancer stem cells. Assume that all the random
variables, rx, follow a Poisson distribution with mean mx, given by equation (4.9),
and that they are independent. Note that the Poisson distribution seems to be a
good choice given the very small probability of a mutation u.
Consider the clone initiated by a mutant cancer stem cell which originated
when there were x wild-type cancer stem cells. Assume that the population size of
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such clone follows a continuous-time branching process where in each time step of
length ∆t, a stem cell divides with probability L∆t and dies with probability D∆t.
Let gx(ξ) be the generating function of such clone for which the original mu-
tation happened when S(t) = x. To calculate this generating function we proceed
as follows.
To simplify the notation we let L̃ = L(1 − a − b) and D̃ = Lb + D. Then by
the Kolmogorov backward equation we have
E
[








ξR(t) | R(0) = 0
]
+ (1− (L̃+ D̃)∆t)E
[




since E[ξR(t) | R(0) = 2] = E[ξR(t) | R(0) = 1]2, by independence. The three
terms on the right hand side of (4.10) describe the three possible events occurring
in the interval of time ∆t: the clone-originating mutated cancer cell divides with
probability L̃∆t producing two resistant daughter stem cells, it dies or differentiates
symmetrically with probability D̃∆t extinguishing the clone, or nothing happens
with probability 1− (L̃+ D̃) and we still have the one mutated stem cell. The time
t = 0 in (4.10) is the time of occurrence of the original mutation that generates the
clone, i.e., when the wild-type population is of size x. The time t in (4.10) measures
time starting from this t = 0.
Let g(ξ, t) = E[ξR(t) | R(0) = 1]. As ∆t→ 0 we get
∂
∂t
g = L̃g2 + D̃ − (L̃+ D̃)g. (4.11)
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Solving (4.11) with the initial condition g(ξ, 0) = ξ gives
g(ξ, t) =
(ξ − 1)(D̃/L̃)e(L̃−D̃)t − (ξ − D̃/L̃)
(ξ − 1)e(L̃−D̃)t − (ξ − D̃/L̃)
. (4.12)
Because M ≈ x exp((L̃ − D̃)tM−x), where tM−x is the time it takes for the cancer
stem cells to go from x to M , we obtain the generating function
gx(ξ) = g(ξ, x) ≈
(ξ − 1)(D̃/L̃)(M/x)− (ξ − D̃/L̃)
(ξ − 1)(M/x)− (ξ − D̃/L̃)
. (4.13)
We now denote by T the total number of drug resistant cancer stem cells that
are present when the cancer is detected, i.e., when the total stem cell population
is M . We let GT (ξ) be its generating function. To calculate GT (ξ), we let Kx be
the total amount of resistant cells found at detection whose originating mutation
occurred when there were x sensitive cancer stem cells. Then
GT (ξ) = E[ξ
T ] = E[ξ(K1+...+KM−1)]
= E[ξK1 ] · · ·E[ξKM−1 ]

























Note that, on line four, we used the fact that gx(ξ)
rx is the generating function of
all the rx clones for which the original mutations happened when S(t) = x, that is
the product of rx generating functions gx(ξ).
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4.2.4 The probability of having resistant cancer stem cells at the time
of detection
By (4.14),(4.9),(4.13) we have that the probability of having resistant cancer
stem cells at the time of detection is



















where C = D+Lb
L(1−a−b) . By replacing the summation with an integral, and with a
change of variable, we get















from which we obtain the desired expressions:










if D = 0. Otherwise, when D 6= 0, we obtain

















where C = D+Lb
L(1−a−b) .
4.2.5 The expected value of resistant cells found at detection if re-
sistance occurred
Given (4.18), we calculate the expected value of the number of resistant cells
that are found at detection, assuming that resistance has indeed developed by the
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time of detection. This conditional expectation of resistant cells is given by
























Equation (4.19) is obtained noting that E(T | resistance) = E(T )/PR = G′T (1)/PR.
Here, PR is given by (4.18) and GT is the generating function of the random variable
T , which is the total number of resistant cancer stem cells that are present when
the cancer is detected.
4.2.6 Alternative derivation: Mode’s theory
We consider here the model where both populations are represented by branch-
ing processes and show an alternative way to derive equation (4.17). The stan-
dard theory for these multi-type branching processes can be found in the book by
Mode [76] as well as partially in [3, 56].
Let p(1)(j, k) the probability for one wild-type cancer cell to give birth to j
wild-type cancer cells and k drug-resistant cancer cells. Let p(2)(j, k) be the same
probability for a drug-resistant mother cell.
Then the only values for which p(i)(j, k) is different from zero are the following:
p(1)(2, 0) = (1 − u)(1 − a − b), p(1)(1, 1) = u(1 − a − b), p(1)(1, 0) = (1 − u/2)a,
p(1)(0, 1) = (ua)/2, p(1)(0, 0) = b; p(2)(0, 2)(1 − a − b), p(2)(0, 1) = a, p(2)(0, 0) = b.
Let D = 0.
Let f (1)(s1, s2) and f









f (2)(s1, s2) = (1− a− b)s22 + as2 + b.
(4.20)
Let Z1(t) and Z2(t) be the number of cancer cells at time t, which are wild-
type and drug-resistant respectively. Note that these are both random variables
now. Let F (1)(s1, s2; t) be the probability generating function of the total number of
cancer cells (both types) present at time t, for the process that was started at time
0 by one wild-type cancer cell, that is
∑
j,k
P (Z1(t) = j, Z2(t) = k|Z1(0) = 1, Z2(0) = 0)sj1sk2. (4.21)
Similarly, let F (2)(s1, s2; t) be the probability generating function of the total number
of cancer cells (both types) present at time t, for the process that was started at time
0 by one drug-resistant cancer cell. Note that since we do not consider backward
mutations, F (2)(s1, s2; t) is given by
∑
0,k
P (Z1(t) = 0, Z2(t) = k|Z1(0) = 0, Z2(0) = 1)sk2, (4.22)
that is, it is not a function of s1.
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By formula (2) in [3, page 225] we have that the two probability generating functions
satisfy the following system:






f (1)[F (1)(s1, s2; t− y), F (2)(s2; t− y)]Le−Lydy,




f (2)[0, F (2)(s2; t− y)]Le−Lydy.
(4.23)
These equations can be differentiated side-by-side to yield the following system




= −LF (1) + Lf (1)(F (1), F (2)),
dF (2)
dt
= −LF (2) + Lf (2)(F (1), F (2)).
(4.24)




= L(1− u)(1− a− b)(F (1))2 − L(1− a+ au
2
)F (1)+
+Lu(1− a− b)F (1)F (2) + Lua
2
F (2) + Lb,
dF (2)
dt
= L(1− a− b)(F (2))2 − L(1− a)F (2) + Lb.
(4.25)
Note that we have already solved the second equation in (4.25), it is equation (4.12),
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with D̃ = Lb,
F (s2, t) =
(s2 − 1)(D̃/L̃)e(L̃−D̃)t − (s2 − D̃/L̃)
(s2 − 1)e(L̃−D̃)t − (s2 − D̃/L̃)
. (4.26)
Now we can substitute (4.26) in the first equation of system (4.25). However, note
that the resulting equation for F (1) does not have a known closed-form solution.
Thus, perturbation methods are needed to obtain an approximate solution, as done
in [39], and even in that case the approximation does not appear to be satisfactory,
as acknowledged by the same authors in [39], since it does not provide a good fit for
the values obtained by simulating the process numerically. Finally note that, once
we obtain F (1), the probability to have resistance developed by the time the tumor
is detected is given by PR = 1 − F (1)(1, 0;T ) , where T is the time of detection of
the tumor.
4.3 Results
We have considered the different ways in which a stem cell may divide (shown
in Figure 4.1): (1) asymmetric division in which a stem cell divides into one pro-
genitor cell and one stem cell (with probability a); (2) symmetric differentiation
in which a stem cell divides into two progenitor cells (with probability b); and (3)
symmetric renewal in which a stem cell divides into two stem cells (with probability
c = 1− a− b).
All three possibilities have been experimentally observed (see [78, 118, 69,
119]). Generally, these three modes of division coexist. Growth curves for different
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Figure 4.2: Growth curves for the stem cell population. (A) Predomi-
nantly asymmetric division: a = 0.75 and b = 0.01. (B) Predominantly
symmetric differentiation: a = 0.2 and b = 0.6. (C) Predominantly sym-
metric renewal: a = 0.2 and b = 0.05. In all plots D = 0.2 and L = 2.
choices of parameters are illustrated in Figure 4.2. We recall that the division rate
is denoted by L, the death rate by D, and the mutation probability per cell division
by u. When a tumor is detected, the number of cancer stem cells is assumed to be
M . Note that this M is different than the M that was used in (4.1) where it denoted
the total number of cancer cells. An example of the time course of the growth of
the drug resistant population versus the sensitive one is shown in Figure 4.3.
First, we have computed the expected number of mutations occurring when
there are exactly x wild-type (drug-sensitive) cancer stem cells in the population.











Figure 4.3: An example of the growth of drug-resistant cancer stem
cells R(t) versus the sensitive ones S(t). The parameters are a = 0.2,
b = 0.05, D = 0.2, L = 2, and u = 4 · 10−7.
Note that mx is independent of x, a result which is not surprising since when the
population is large there are many more cells which may divide but also substantially
less time for them to do so before the population increases to x+ 1. A similar result
was obtained using Markov chains in [50].
Our next result has been the calculation of the probability, PR, that at the
time of detection, there are cancer stem cells that developed resistance to the drug.
If the death rate D is assumed to be zero, then this probability is given by (4.17)










Otherwise, when D 6= 0, we obtain (4.18)


















where C = D+Lb
L(1−a−b) . We note that equation (4.18) is an extension of equation (4.1)
(which can be recovered by setting a = b = 0, and setting M as the total population
size).
Given (4.18), we have also calculated the expected value of the number of
resistant cells that are found at detection, assuming that resistance has indeed de-
veloped by the time of detection. This conditional expectation of resistant cells is
given by (4.19)












Having obtained these results, we would like to demonstrate their significance
by considering a concrete problem. Our goal is to study the division pattern of
hematopoietic leukemic stem cells in chronic myeloid leukemia (CML). This can be
accomplished by estimating the probabilities a, b, and c in CML.
It is estimated that in CML, the leukemic stem cell population at early detec-
tion is of the order ofM ≈ 2.5·105 cells [47, 73]. It is also estimated that the probabil-
ity of a random point-mutation conferring resistance to imatinib is u ≈ 4 · 10−7 [73].
The turnover rate D/L is estimated to be in the range 0.1 − 0.5 [110]. The model
parameters are summarized in Table 4.1.
A recent clinical study [45] follows CML patients that have been treated with
imatinib over a period of 6 years. It is shown that no more than 15% of the patients
stop responding to the drug at some point during this time period. Interestingly,
after 5 years, patients seem to stop relapsing, at least during the time-frame of the
study. Since it has been recognized that imatinib has a positive effect on eliminating
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Table 4.1: Model parameters
Parameter Description Estimate
M Cancer stem cell population at detection 2.5 · 105
u Mutation rate 4 · 10−7
D/L Turnover rate 0.1 – 0.5
differentiated leukemic cells, the cases of observed relapses must be traced back to
the subpopulation of leukemic stem cells that developed resistance to imatinib. This
implies that the probability that cancer stem cells mutated and developed resistance
to imatinib by the time of detection cannot exceed 15%, a figure that can be used as
an upper bound on the probability of developing resistance by the time the disease
is detected, PR.
Using these estimated parameters, we use equation (4.18) to fit the parameters
a and b; c is then given by 1 − a − b. In Figure 4.4 we plot the range of a and b
for which PR < 0.15. In this case we set the turnover rate D/L = 0.1. Clearly, the
figure indicates that in order for PR < 0.15, a and b must be relatively small. For
example, if a = 0.87 and b = 0.01 then PR = 0.71. However, if a = 0.2 and b = 0.05
then PR = 0.12, which is in the desirable range. Similar results are obtained for
other values of the turnover rate. The larger D/L is, the smaller the admissible
region is.
This result is not surprising for the probability of a symmetric differentiation,
b, which is typically estimated to be very small. However, the estimated value of
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Figure 4.4: The range of a and b for which PR < 0.15. The turnover rate
is D/L = 0.1.
the asymmetric division probability a is interesting, since it has been observed that
for healthy hematopoietic stem cells, a should be close to 1, and generally above
0.9 [5, 28].
These estimates suggest that leukemic hematopoietic stem cells should have
a much lower than normal tendency to divide asymmetrically (i.e., a low a), hence
making a substantial shift toward an increased symmetric renewal.
4.4 Discussion
The main result of Iwasa et al. [50] is given by equation (4.1). How should this
equation be understood given actual estimates of the parameters? We recall that
in (4.1), the parameter M is the total number of cells in the tumor. At present, an
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approximation of the lower limit of clinical detection of solid tumors is M ≈ 109,
see, e.g., [92, page 31]. For the mutation rate, a common estimate is on the order
of u > 10−8 (see [63, 111]). Hence, according to the results of Iwasa et al., since
(L/D) ln(L/(L−D)) > 1 if D < L, the probability that resistance develops by the
time a tumor is detected must be always greater than .9999.
Another quantity of interest is the expected number of resistant cancer cells
found at detection Ȳ , assuming that resistance developed. An estimation of Ȳ is
given in [50] by equation (4.2). Unfortunately equation (4.2) is valid only when
Mu  1, which is not the case when M = 109 and u = 10−8. Hence, we estimate
Ȳ for M = 106 and u = 10−8, which according to (4.2) is Ȳ > 13. Consequently,
for M = 109 we could expect thousands of mutated, drug-resistant cancer cells.
Such a result implies that resistance should always be present in large numbers at
the detection time. Therefore, clones that are generated by such resistant cells are
invulnerable to the treatment. They will expand, and no patient will be able to
survive the disease in the long run. This result is in contradiction with clinical
data. It turns out that, e.g., among CML patients that are treated with imatinib
in the chronic phase, only in less than 15% of the patients the drug is unable to
keep the disease under control which results in a relapse [45, 73]. The apparent
contradiction between the mathematical analysis and the experimental data suggests
that something may be missing from the modeling assumptions of Iwasa et al..
Alternatively, the experimental estimates of the mutation rates might have to be
adjusted.
This dichotomy has been addressed in recent works, e.g. [73, 98], in which the
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modeling assumptions include a heterogeneous tumor population, comprising from
stem cells and other cells that are at various stages of maturation. For example,
Michor et al. focus only on the stem cell compartment and accordingly use a much
smaller value as an estimate for M [73]. Hence, they effectively think of M as
the number of cancer stem cells found at cancer detection, and not as the total
number of cells in the tumor. As already mentioned in the Results Section, it
is estimated that in the case of CML in the early chronic phase, the stem cell
population at detection is approximately 2.5 ·105 cells and the mutation probability
u is approximately 4 · 10−7. With such values in mind, Michor et al. obtain an
estimate (using formula (4.1) with D/L = 0.5) for the probability of resistance
mutations present at the time of diagnosis. This probability is calculated in [73] to
be approximately 13%, an estimate that is in agreement with the data [73, Table
1]. Unfortunately, the methodology of [73] is based on applying the results of [50]
to small cell populations in order to consider only stem cells. The problem with
this approach is that equation (4.1) was derived assuming a homogeneous tumor
population. It is not valid for describing the dynamics of stem cells, and should not
be applied directly to heterogeneous populations as done in [73].
In contrast, the model that we study in this work is based on the “stem cell
hypothesis”. It incorporates the different ways a stem cell may divide and studies
the dynamics that emerges due to these division paths. We would like to emphasize
once again that from the point of view of drug resistance, the heterogeneity in the
tumor cell population implies that it is only the stem-like long-lived cells, those
cells that have the ability of self-renewal, that propagate the drug resistance. Any
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model of drug resistance in cancer must therefore take into account the cancer stem
cells. Cancer cells that do not have self-renewal capabilities, cannot propagate the
resistance in the long run, and should be disregarded.
In order to address the heterogeneity of the tumor cell population we chose to
simplify the mathematical tools. In modeling the wild-type cancer stem cell popu-
lation we replace the Markov chains that were used in [50] by ordinary differential
equations. Our approach amounts to using a deterministic model which considers
the averaged behavior of such a population. Intriguingly, notwithstanding such sim-
plification, our approach provides identical results to those found in Iwasa et al. if
we also assume a homogeneous cell population. This can be immediately obtained
by setting a = 0, and b = 0 in equations (4.17)–(4.18). Thus, in the context of the
specific questions we are studying, nothing is lost by using a partially deterministic
approach. On the contrary, our simplified approach enables us to extend the results
of [50].
The prediction of a large shift from asymmetric division to symmetric renewal
of hematopoietic stem cells in CML is an important examples of what the mathe-
matical modeling of drug resistance can tell us about cancer. Our estimates were
based on a resistance probability of approximately 15%. If instead, we use a less
conservative estimate that the probability of resistance is less than 10% (as could
be interpreted from the data in [45]) then the conclusion of our study is that cancer
stem cells must generally renew symmetrically.
In order to discuss the confidence level at which the conclusions were obtain,
we make the following observations on the sensitivity to the parameter estimates
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and on certain extensions of the model.
It is important to comment on the sensitivity of the result on the shift from
asymmetric division to symmetric renewal to the parameter estimates. It is easy to
check that reasonable variations in the turnover rate do not affect our conclusion.
With respect to the dependence on the estimates of M and u, it seems unlikely
that the estimate for M , the cancer stem cell population size present at the time
of detection, would be much smaller than what is estimated in the literature [47].
Rather, it appears reasonable to assume that for many patients, M will actually
be larger (depending on the detection time). In this case, there must be an even
more substantial shift toward symmetric renewal. The same is true for the mutation
probability u. If u is larger than the estimated value then there will have to be an
even stronger shift to symmetric renewal in order to explain the clinical data.
Our calculations did not include the possibility of recruitment of progenitor
cells (and their offsprings) into the cancer stem cell compartment. It is possible
that progenitor cells whose normal function has been perturbed will acquire stem-
like self-renewal properties [62]. However, we note that if such a recruitment takes
place, this would only strengthen our result. The total amount of drug resistance
that is found at detection and is due to the original compartment of cancer stem
cells would have to be smaller than our original estimates due to the recruitment
of progenitors. In this case, the probability of asymmetric division would be even
smaller than our current estimates. Our model also did not take into account gene
amplification, a cellular process which amplifies the phenotype that the gene confers
on the cell, preventing the absorption of the drug by the cell. However, a similar
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reasoning to the case of recruitment of progenitor cells, shows that the inclusion of
this kind of resistance would again only strengthen our conclusions.
Our results do not contradict the somewhat sparse experimental data. In
the contrary, there is some experimental evidence to support the hypothesis that
cancer stem cells change their mode of division. For example, it has been observed
that when the mechanism regulating asymmetric divisions is disrupted, Drosophila
neuroblasts begin dividing symmetrically and form tumors [64]. It is also known
that some gene products can both induce symmetric cell divisions and function as
oncogenes in mammalian cells [64, 95]. Thus there seems to be a link between
symmetric divisions and cancer progression.
It could be of great interest in our model could be tested experimentally, at
least in vitro, on cancer cell lines. Ideally, a direct experimental method would
require to isolate cancer stem cells and healthy stem cells and compare the growth
of both stem cell populations.
From a methodological perspective, the mathematical analysis allows us to
use indirect information about the mechanisms that control the dynamics of the
disease evolution to reach specific conclusions that go beyond the present reach
of experiments. While we have applied our mathematical results to the available
clinical data on CML, the approach is not limited to this specific disease, and we
expect similar conclusions about the division of cancer stem cells in other types of
cancer as well. Specifically, our model should apply to any cancer for which stem
cells our known to be the driving force of the progression of the disease and for
which point mutations are a source of drug resistance.
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Chapter 5
An Extension of the Stem Cell Model
5.1 Introduction
There have been many attempts in the literature to model and simulate tumor
growth. Clearly a specific growth curve will depend on a very large number of factors,
for example, the type of tumor, its location, and patient-specific characteristics. Due
to its simplicity, an exponential growth has been the most commonly used curve in
cancer modeling, and we also have made use of it in the previous chapters. For the
initial phase of a tumor growth, the exponential curve appears to be a reasonable
approximation.
However, because of limits in space and nutrients, tumors generally appear to
slow down their growth after having attained a certain size. Exponential growth
models do not reflect this critical saturation. Thus, exponential cancer growth may
be a good assumption only when the cancer population is small. To account for the
more advanced phases of the tumor, the logistic and Gompertz growth models have
been successfully introduced, as in the celebrated work on the modeling of human
breast cancer by Moolgavkar [77], where the logistic curve was used.
For a recent example we refer to Nakasu et al. [80], where various growth curves
are compared by the authors in the case of meningiomas in order to determine which
one provides the best fit to the data. Nonlinear regression analyses were performed
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against power, exponential, logistic, and Gompertzian curves. Their conclusion was
that Gompertzian and logistic growth curves gave the best fit. Interestingly they
found that atypical meningiomas continue to grow quasi-exponentially.
Surprisingly, more realistic models of tumor growth have not been fully inte-
grated into existing mathematical models of drug resistance. In the literature on
drug resistance, there are some works in which the possibility of considering non-
exponential tumor growth types is mentioned, for example in [58]. However, to the
best of our knowledge, for the case of non-exponential tumor growth there are no
estimates of the probability, PR, that, by the time a tumor reaches detection size,
drug resistant stem cells are already present. One possible reason is given by the fact
that to replace the exponential curve with any other growth model is mathemati-
cally a more complex undertaking, especially when dealing with stochastic methods.
Moreover the Markovian assumptions, that are usually inherent to the stochastic
models, require exponentially distributed times, thus making it very natural to use
the corresponding exponential growth.
In this chapter we extend our previous results by replacing the exponential
cancer growth model by more realistic models. The simplicity of our methodology
allows us to obtain an estimate for PR for the case of logistic tumor growth. Fur-
thermore we are able to draw some conclusions for more general growth models. In
this sense, this chapter represents an extension of the stem cell model found in the
previous chapter and a generalization of its results. For example, the exponential
growth model can be seen as a logistic growth model where the carrying capacity is
infinite.
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5.2 The logistic case: model derivation
As in Chapter 4, we adopt a mixed technique and derive the mathematical
model using ordinary differential equations (ODEs) for the wild-type cancer popu-
lation and branching processes for the mutant cells.
5.2.1 Ordinary differential equations
Recall that cell division rate is denoted by L, the death rate by D, and the
mutation probability per cell division by u. As in the previous chapter, a denotes
the probability of an asymmetric division, b the probability of a symmetric differen-
tiation, and c = 1− a− b the probability of a faithful symmetric renewal. When a
tumor is detected, the number of cancer stem cells is assumed to be M . We denote
the total number of wild-type, i.e., drug-sensitive cancer stem cells at time t by S(t).
The second group of cells, the mutated cancer stem cells that developed resistance
to the drug, are denoted by R(t).
Importantly, these populations are now assumed to grow logistically. The
dynamics of the averaged behavior of the two cell populations can then be described
using the following system:
S ′(t) =
[
































which accounts for the carrying capacity K of the logistic growth, where S(t) must
be less than K for all t, and also M < K. The initial conditions for (5.1) are given
by S(0) = 1 and R(0) = 0.
Given that the mutation rate u is very small, it can be eliminated from the
first equation. However, it cannot be removed from the second equation since S(t)
is much larger than R(t). The system (5.1) can be thus reduced to the following:




























5.2.2 The expected number of mutations when the size of the wild-
type population is x
Using system (5.2) we estimate the expected number of mutations, mx, that




1 + (K − 1) exp[(L(1− a− 2b)−D)t]
. (5.3)
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This means that the “average” time at which the wild-type cancer stem cell popu-









Thus the “average” length of time for which the population will consist of exactly
x stem cells is




















Hence, the “expected number” of mutations occurring when there are exactly x














This expression is obtained by multiplying the number of wild-type stem cells present







, and by the length of
time for which the total stem cell population equals x.





















Interestingly, this is exactly the same expression found for the exponential growth
case, equation (4.9). There is an intuitive way to understand why the expected
number of mutations occurring when there are exactly x wild-type cancer stem cells
turns out to be the same expression when assuming an exponential model or a
logistic model for the cancer growth: the closer the cancer stem cell population is
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to the carrying capacity K the smaller the division rate but also the larger the time
spent by the tumor in the state S(t) = x. The two effects turn out to balance each
other.
5.2.3 Branching processes
Assume now that the tumor population grows logistically starting from one
wild-type stem cell. Let rx be the actual number of mutations produced when
there are x = 1, 2, . . . ,M − 1 wild-type cancer stem cells. Assume that all random
variables, rx, follow a Poisson distribution with mean mx, given by equation (5.7),
and that they are independent.
Consider the clone initiated by a mutant cancer stem cell which originated
when there were x wild-type cancer stem cells.
Assume that the population size of such clone follows a continuous-time branch-












that births and deaths occur according to an exponential distribution with param-





















S(0) + (K − S(0)) exp(−rt)
, (5.8)
where r := (L(1 − a − 2b) −D). Thus, for a clone of mutants generated when the
wild-type population was equal to S(t) = x, we have that births and deaths in such
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x+ (K − x) exp(−rt)
)
= L(1−a−b) K − x











(K − x) + x exp(rt)
(5.10)
respectively. Here time is measured starting from the generation of the clone.
Let gx(ξ) be the generating function of such a clone for which the original
mutation happened when S(t) = x. Then, by the Kolmogorov backward equation,
we have as in (4.10) for the exponential case,
E
[








ξR(t) | R(0) = 0
]
+ (1− (L̃(t) + D̃(t))∆t)E
[




since E[ξR(t) | R(0) = 2] = E[ξR(t) | R(0) = 1]2, by independence. The time t = 0
in (5.11) is the time of occurrence of the original mutation that generates the clone,
i.e., when the wild-type population is of size x. The time t in (5.11) measures time
starting from this t = 0.
Let g(ξ, t) = E[ξR(t) | R(0) = 1]. As ∆t→ 0 we get
∂
∂t
g = L̃(t)g2 + D̃(t)− [L̃(t) + D̃(t)]g, (5.12)
again a Riccati equation as for the exponential growth case (see equation 4.11), but
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(K − x) + x exp(rt)
[L(1− a− b)g2− (L(1− a− b) + (Lb+D))g+ (Lb+D)].
(5.13)
Solving (5.13) with the initial condition g(ξ, 0) = ξ gives























Since M ≈ xK
x+(K−x) exp(−rtM−x)
, where tM−x is the time it takes for the cancer stem
cells to go from x to M , by letting exp(rtM−x) =
M(K−x)
x(K−M) into (5.14) we obtain the
generating function












We denote by T the total number of drug resistant cancer stem cells that are
present when the cancer is detected, i.e., when the total stem cell population is M .
Finally we let GT (ξ) be its generating function and recall that, by (4.14),
GT (ξ) = E[ξ









5.2.4 The probability of having resistant cancer stem cells at the time
of detection
By (5.7),(5.15),(5.16) we have that the probability of having resistant cancer
stem cells at the time of detection is






















By replacing the summation with an integral, and with a change of variable, we get















from which we obtain













It is immediate to see that such expression is equivalent to

















where C = D+Lb
L(1−a−b) . It is important to note that equation (5.20) is precisely equa-
tion (4.18), obtained for the exponential growth case. Finally, given (5.19), it follows
that the expected value of the number of resistant cells that are found at detection,
assuming that resistance has indeed developed by the time of detection is given by












as in the exponential growth case.
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In summary, we have calculated the probability, PR, that by the time a tumor
reaches detection size, there are drug resistant stem cells in a logistically growing
cancer population. We have found that this probability, given by equation (5.19),
is the same as for the exponential growth case. This result may appear somewhat
surprising. However, it can be explained by making the following observation. We
note that the closer the cancer stem cell population is to the carrying capacity, K,





∆t (which in the
exponential growth case is constant) but also more time is spent by the cancer stem
cells in the state S(t) = x, with the two effects balancing each other.
The simplicity of our methodology allowed us to obtain an estimate for PR
and E(T | resistance) for the case of a logistic tumor growth. We would like to
note that arguably our modeling methodology may be seen as more general, in
the sense that at least for the wild-type population we only made assumptions on
their averaged behavior. We only assumed that, on average, the cancer stem cell
population grows logistically. We did not assume, for example, that the time to
division is exponentially distributed or that the Markov property holds.
5.3 On other types of tumor growth
While a logistic term has been used successfully to model tumor growth, there
are many other possible types of growth that can be considered. Thus, it is natural
to ask whether our result, on the probability to find resistance by the time of tumor
detection, is independent of the averaged way in which the cancer stem cells grow.
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Would we get the same estimate for the probability PR if the average growth of the
tumor population were to be for example a Gompertz law or a power law rather
than exponential or logistic?
While we do not have a complete answer, we would like to make the following
observation about a possible generalization of our results. Consider the following
system:
S ′(t) = [L(1− a− 2b)−D]f(t)S(t),
R′(t) =
[










with S(0) = 1 and R(0) = 0. Here f(t) is any strictly positive real function of t.
Naturally we may have f(t) = g(S(t)) for some strictly positive real function g.
The only difference with (5.2) is that now we allow for a much more general
form of tumor growth. The system (5.22) includes both the exponential and the
logistic growth cases considered previously, as well as many other types of growth
like, for example, the Gompertz law.
From the first equation of system (5.22) we have that
∆S(t) = S(t+ ∆t)− S(t) ≈ [L(1− a− 2b)−D]f(t)S(t)∆t. (5.23)










Hence, the “expected number” of mutations occurring when there are exactly x




















Note that equation (5.25) is identical to the corresponding results that were derived
in the exponential growth model (see equation (4.9)) and in the case of a logistic
growth model (see equation (5.7)). Note that we could obtain the same result in
the even more general case where S ′(t) = [L(1− a− 2b)−D]f(t).
For simplicity, let D = 0 and b = 0. In this case, every time a mutation occurs
the resulting clone will never become extinct. This means that the probability, PR,
that by the time a tumor reaches detection size there are drug resistant stem cells
in the cancer population will be given by










which is the same expression found for the exponential and logistic cases, given by
equation (4.17). Thus, at least for the case where D = 0 and b = 0, formula (5.26)
applies to very general tumor growth models and the probability to find resistance
by the time of tumor detection is independent of the way the cancer stem cell
population grows on average. While we are not able to give a complete answer for
the case where D 6= 0 and b 6= 0, the experimental evidence indicates that b ≈ 0
(see [5, 28]) and D is very small compared to L. In fact, some researchers consider
stem cells as eternal [1, 41], which corresponds to D = 0. In conclusion, our results
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seem to be a good approximation for a rather general model of cancer growth.
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Chapter 6
On Resistance to Imatinib in Chronic Myeloid Leukemia
6.1 Introduction
Chronic myeloid leukemia (CML) is a cancer of the white blood cells. It
causes unregulated proliferation of immature blood-forming myeloid cells in the bone
marrow, leading to accumulation of mature granulocytes (neutrophils, eosinophils,
and basophils) and their precursors in the bone marrow and in the blood. The
hematopoietic (blood cells) system is depicted in Figure 1.1.
CML is characterized by a chromosomal translocation between chromosome 9
and 22 known as the “Philadelphia chromosome”. As a result, the fusion gene BCR-
ABL is created, which encodes the bcr-abl fusion protein, a tyrosine kinase. This
enzyme is able to transfer a phosphate group from ATP (Adenosine-5’-triphosphate)
to a protein, by attaching it to the amino acid tyrosine. This phosphorylation
controls the properties and function of the protein receiving the phosphate group.
Specifically, it has been shown that the bcr-abl tyrosine kinase contributes via tyro-
sine phosphorylation to growth factor independence, increased proliferation, genetic
instability and suppression of apoptosis in leukemic cells (see [70, 96, 45] and the
references therein). The methods used to detect the “Philadelphia chromosome”
are bone marrow cytogenetics analysis, which studies directly the chromosome, and
reverse transcriptase polymerase chain reaction (RT-PCR), which enables detection
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of residual leukemic cells at the level of one cell in 105 − 106 normal cells by mea-
suring the levels of bcr-abl transcripts in the blood of the patient and obtaining an
estimate of the fraction of terminally differentiated leukemic cells (see Branford et
al. [6]).
There are three distinct clinical phases in CML. Most people are diagnosed
with CML during the so called “chronic phase” (CP), as a result of a routine blood
test showing an elevated white blood cell count, which leads to further investiga-
tions. Patients in this phase are either asymptomatic or with mild symptoms of
fatigue, fever, easy bleeding or abdominal pain. In this phase the concentration
of myeloblasts in the blood is above normal limits. The myeloblast is a unipotent
stem cell, which differentiates into one of the mature granulocytes. As the dis-
ease progresses, patients enter an “accelerated phase” (AP), when the percentage
of myeloblasts in the blood or bone marrow reaches 10 - 19%, followed by a almost
invariably fatal “blast crisis” (BC), in which the hematopoietic differentiation has
become arrested and many immature myeloblasts fill much of the bone marrow (at
least 20%) and are found in high concentrations in the blood [70, 115].
As of today, allogeneic stem-cell transplantation is the only known cure able
to eradicate the disease. However, the success of transplantion is limited, because
the procedure is viable in approximately 25% of the patients and relapses occur in
20 - 30% of cases [48, 86].
The recently introduced drug Imatinib (also known as STI571, Gleevec, and
Glivec) is a potent inhibitor of the bcr-abl tyrosine kinase. After 18 months of
treatment, a complete cytogenetic response (CCyR) is achieved in 87% of previ-
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ously untreated patients, thus dramatically improving patients’ survival [86]. CCyR
is defined as the complete absence of detectable bcr-abl transcripts in the blood,
that is, when 0% of detectable blood cells are Ph+ (Philadelphia chromosome posi-
tive). Because of its ability to directly target the bcr-abl protein, Imatinib mesylate
belongs to the group of the so called “targeted therapies”. These drugs differenti-
ate themselves from the more traditional chemotherapeutic treatments by targeting
molecules specifically involved in tumor growth rather than attacking all (healthy or
not) rapidly dividing cells. Specifically, Imatinib works by blocking the ATP binding
site of bcr-abl, thus inhibiting the enzyme activity, e.g. [102, 19]. This mechanism
is depicted in Figure 6.1. This fact explains why point mutations in the bcr-abl
domain can cause resistance to Imatinib [68].
The structure of the chapter is as follows. In Section 6.2, we review the most
recent data available on CML patients treated with Imatinib and make a series of
key observations. In Section 6.3, we briefly review the basic modeling assumptions
and main results found in the mathematical modeling literature on CML and the
related development of drug-resistance. In Section 6.4, we use our observations to
formulate a new hypothesis, which is able to explain, for the first time, the most
recent data on CML. In Section 6.5, we provide new insights on the diagnostic and
therapeutic strategies against CML.
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Figure 6.1: The effect of Imatinib on the bcr-abl tyrosine kinase.
(Sodium; commons.wikimedia.org under GNU Free Documentation Li-
cense).
86
6.2 The data and some key observations
In this section we consider the most recent data found in the literature on
CML patients treated with Imatinib. In particular we refer to the data coming from
the largest international clinical trial, known as the IRIS (International Randomized
Study of Interferon vs STI571) trial (see for example Hochhaus et al. [45]), where
1106 previously untreated CML patients in chronic phase were randomized, between
June 2000 and January 2001, to receive treatment with Imatinib (553 patients) or
interferon-α (IFN) plus cytarabine (553 patients). IFN plus cytarabine represented
the standard treatment for CML patients in chronic phase at the time of the begin-
ning of this trial (see [86]). Furthermore we also consider some patient-specific data
published in Branford et al. [7] and Michor et al. [73].
We make the following observations derived from the data on Imatinib.
1. At 18 months into the trial, Imatinib provided complete cytogenetic responses
for 76.2% of the patients versus 14.5% obtained with interferon-α (IFN) plus
cytarabine (see [38, 86]). Thus, as a result of the data from the first years of
this IRIS trial, Imatinib has become the standard first-line therapy for patients
with newly diagnosed CML in chronic phase [86]. Of 553 patients originally
on the IFN-α plus cytarabine treatment, 359 crossed over to Imatinib, 181
patients discontinued treatment, and only 13 patients remained on IFN-α plus
cytarabine treatment (see [38]).
2. At 48 months after starting Imatinib, the estimated percentages of freedom
from progression to accelerated phase or blast crisis was 91%. After 54 months
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under treatment, 81% of patients had a complete cytogenetic remission [38].
At 72 months, both of these percentages were basically unchanged [45].
3. For CML patients in CP, within few months after the start of treatment, the
vast majority of leukemic cells had generally died out (see [73]).
4. In the presence of point mutations or gene amplification, there are drug-
resistant cells that survive and generally will cause a relapse and progression
of the disease to AP and BC (see [7, 73]).
5. It appears that drug-resistant cells are not the only problem. Indeed if Ima-
tinib is removed, even after up to three years into the treatment, often the
disease relapses almost immediately and quickly reach levels at or beyond the
pre-treatment baseline. Thus Imatinib does not seem to be able to completely
eradicate the disease [73].
6. As long as a CML patient in CP does not discontinue the treatment and as
long as there is not the development of resistance, the disease is generally kept
under control in the long run [45] .
7. Importantly, relapses due to drug resistance seem to stop occurring at around 5
years into the treatment [45]. Note how in Figure 6.2, the “curve” for relapses
has a peak around two years and then approaches zero around 5 years. This
is somewhat similar to the case of relapses in bone marrow transplants.
8. Finally, we would like to note that a consequence of the stem cell hypothesis
is that long-lived resistance will be only caused by those cells that have the
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Figure 6.2: The annual event rates for patients under treatment with
Imatinib in the IRIS study. The red bars represent the progression of the
disease to an Acute Phase or Blast Crisis (AP/BC). The blue bars include
all other events (Based on Figure 2 in Hochhaus et al. [45]).
89
ability of self-renewal, that is the stem-like cells. Thus, for the problem of
drug resistance, we may focus only on them [114].
6.3 Current mathematical models of CML which include the stem
cell hypothesis
There is a growing literature on mathematical models of CML which include
the stem cell hypothesis among their assumptions. Of particular relevance are the
two Nature papers by Michor et al. [73] and Roeder et al. [98], as well as the work
by Kim et al. [55], Komarova et al. [61], Dingli et al. [16], Michor et al. [74, 72] and
Foo et al. [23]. In this section we briefly review some of the main assumptions and
conclusions of [73, 98, 23].
6.3.1 Michor et al.
Michor et al. [73] uses the stem cell hypothesis in analyzing the dynamics of
chronic myeloid leukemia (CML). In their hierarchical model the leukemic popu-
lation is divided into four sub-populations: stem cells (the only cells with an in-
definite potential for self-renewal), which give rise to progenitors, which produce
differentiated cells, which in turn produce terminally differentiated cells. Thus a
four-compartmental ODE system is used, where the coefficients are estimated using
a 169-patient data set. Clearly the dynamics of this system are somewhat differ-
ent from those obtained by modeling the tumor as homogeneous. More precisely,
there are three sets of equations in this model: a set of equations for healthy cells,
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a set of equations for leukemic cells, and a set of equations for leukemic mutated
drug-resistant cells. Each set of equations has four equations in order to account
for the dynamics of stem cells, progenitor cells, differentiated cells, and terminally
differentiated cells. Also, it is not assumed in the model that the drug kills any
cells. The action of the drug in this model is accounted for with a lower (than
normal) proliferation rate for the leukemic cells and is done through the terms for
the proliferation rate constants of the leukemic progenitor, differentiated and fully
differentiated cells respectively.
A fundamental assumption of the model is that Imatinib is not able to affect
the leukemic stem cell compartment. The reasons behind this assumption are the
experimental evidence that, even if the drug has been administered for as long
as three years, there is a relapse of bcr-abl transcripts within three months after
discontinuation (see [73, 12]), and the fact that leukemic stem cells appear to be
insensitive to the drug (see [35, 67]). Thus, in this model, the cells that are resistant
to the drug are both the leukemic stem cells (LSCs) and the entire hierarchy of
mutated drug-resistant cells. Additionally, the model has no upper limits on the
proliferation of the LSCs.
Therefore one of the main assumptions of the paper is that Imatinib is not
able to deplete the leukemic stem cell compartment. The probability of developing
resistance to Imatinib by the time of detection is also calculated using formula (4.1),
and estimated at 13%, which fit well with the data (see [73, see table 1]).
Remarks:
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1. The model predicts that, over time, leukemia always wins, since the LSC
compartment can do nothing else other than to keep growing. This is due to
the assumptions of the model that LSCs are not affected by the drug and their
growth is not constrained by saturation. Thus, overall, patients should not be
able to survive.
2. Importantly, because of what mentioned in Remark 1, drug resistance should
propagate throughout the uninterrupted production of LSCs and of mutated
cells. Thus, it should be possible to see patients who relapse at any point in
time after the start of treatment.
3. The issues raised in Remarks 1 and 2 are clearly in contradiction with the
up-to-date data (see [45]), where actually we see the majority of the patients
survive and the disease is kept under control with Imatinib. Furthermore, in
the data reported in [45], there is no evidence of relapses after the fifth year,
that is, after a peak at around two years into the treatment, the rate of relapse
appears to go to zero at around 5 years.
4. Finally note that the probability of developing resistance to Imatinib by the
time of detection was calculated using formula (4.1), which is derived from a
model where the cancer population is assumed to be homogeneous and not a
hierarchical one (see [50]). However this is in contradiction with the fact that
the model by Michor et al. assumes the stem cell hypothesis. It is indeed clear
that the dynamics should be different.
In summary: the model by Michor et al. [73] would predict that over time,
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the disease would progress for all patients, as there is no mechanism to stop the
propagation of LSCs and of drug resistance. This is clearly not the case.
6.3.2 Roeder et al.
In a recent paper, Roeder et al. [98] have proposed a model for the dynam-
ics of the relapse in chronic myeloid leukemia (CML) where the role of quiescent
G0 stem cells and their ability to escape Imatinib-induced apoptosis was included.
Roeder et al. assume that the stem cells are divided into two compartments: active
and quiescent. With certain probabilities, stem cells can pass between the compart-
ments. Only stem cells that are in their active state can proliferate. The transition
between the compartments is based on some internal counter - named “affinity” -
which increases over time (though upper bounded) and is related to the transition
probabilities. There is actually no data to support the existence of an “affinity”
parameter, even though the experimental data do support a model in which stem
cells can be active or dormant. What causes them to shift between the states is un-
known. In this model, the drug does affect LSCs, an important difference between
this model and [73]. However, it acts only on the active cells, which is a reasonable
assumption. In such a model, over time, drug resistance will develop in the active
LSC compartment. Since LSCs shift between compartment, the drug resistance can
then propagate from the active cells into the dormant compartment, and stay there
indefinitely. In such a way, even if all active LSCs were eliminated, LSCs that are
resistant to the drug may still return to the system by shifting out of the dormant
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state. However, if wild-type LSCs became active during treatment they would be
eliminated, thus there should not be progression of the disease for patients under
treatment who did not develop drug resistance before the start of the treatment;
rather the disease should be eradicated in these patients. The prediction of Roeder’s
model is that Imatinib has the potential to induce a complete eradication of the dis-
ease in the long run, except for those patients who developed drug resistance. There
are several remarks we would like to make about this model.
Remarks:
1. The model predicts that Imatinib has the potential to induce a complete cure
from the disease, in the long run, for patients under treatment who did not
develop drug resistance before the treatment starts. The logic is as follows.
The active LSCs would be eliminated by the drug. The quiescent LSCs in-
stead would need to become active in order to proliferate. Thus, we could
expect these reactivated LSCs to be typically eliminated by the drug before
the mutation hits, given that mutations are rare events. Usually, then, pa-
tients should be able to reach complete remission from the disease. However
the data implies that this may not be the case. Indeed it appears that as soon
as the therapy is interrupted, often (but not always) there is a quick relapse
of the disease (see [73, 12]).
2. Another major concern about this model is that if a temporary remission is
attained due to the residue of LSCs being dormant, once the drug is removed
there is no clear mechanism by which the disease will relapse immediately, i.e.,
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within few weeks, which is instead what has been observed in patients [73, 12].
Furthermore the relapse will often cause an increase in the number of leukemic
cells well beyond the pre-treatment baseline, again something difficult to ex-
plain with this model, given that cycling LSCs are assumed to be eliminated
by Imatinib. Thus, it might be hard to explain with this model and its tran-
sition probabilities, a rapid transition of stem cells between states. Usually,
stem cells are being thought of as having relatively stable and slow dynamics.
It could be that LSCs have somewhat different characteristics, but to the best
of our knowledge, this is unknown.
3. The entire concept of “affinity”, which is an integral part of the works of
Roeder and his co-authors, is not based on any actual biological knowledge.
In particular, it is hard to understand why cells that have been dormant longer
are more likely to become active. Is there really an internal clock involved, or
is the activation of stem cells related to signals that they received, regardless
of the time that they became dormant? The latter is probably a more likely
biological scenario.
6.3.3 Foo et al.
In this work [23], the authors incorporate, as in Roeder et al. [98], the idea of
splitting the stem cells into two compartments: cycling and quiescent. These states
are temporary: quiescent stem cells can start cycling and vice versa. In addition,
they consider the possibility of LSCs being susceptible to the drug. Two possible
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scenarios are considered: the case where all LSCs are completely insensitive to the
drug and the case where only the quiescent LSCs are drug resistant (not because of a
mutation but just due to kinetic resistance), while the cycling LSCs are depleted by
the drug Imatinib. Finally, they assume that there exists an equilibrium, a steady
state for the system, reached by the time of detection, which guarantees that the
total amounts of normal and leukemic stem cells remain constant until the treatment
initiates.
Remarks:
1. The main concern with this model is that it does not explain the data. Indeed
the model makes either one of two opposite predictions: if only quiescent LSCs
are resistant to Imatinib then a full cure will ultimately be obtained (given that
quiescent states are temporary) or Imatinib will ultimately fail if all LSCs are
resistant to it (since the LSC compartment will keep growing and furthermore
more drug resistance will be created).
2. Another problem with this model is not the idea of a level of equilibrium,
which might exist, but the fact that it is assumed that this steady state is
reached before the therapy starts. In reality, an equilibrium, if any, should be
reached much later than at detection time. Indeed, at detection the disease
is usually in chronic phase and not in acute phase or blast crisis, where the
leukemic cell load is much higher. Thus, if we did not take into account the
treatment, after the time of CML detection there would still be a lot more time
for the leukemic cell population to grow in numbers before reaching a level of
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saturation or any possible balance with the healthy hematopoietic population.
6.4 A new hypothesis
In this section, we formulate a new hypothesis driven by the data and the
observations made in Section 6.2.
From observations 4 and 5 of Section 6.2 it follows that Imatinib does not
seem to eradicate the disease. However, under treatment, LSCs do not appear to be
growing in number (see observations 1-3, 6-7). Thus, we hypothesize that the drug
shuts down the division process of all leukemic cells, i.e., it inhibits proliferation
caused by the BCR-ABL rearrangement. Interestingly, there is a general consensus
in the medical literature that this is the effect of Imatinib on leukemic non-stem
cells (see [46, 35, 96, 70, 45] and the references therein). Thus an observed decline
of all types of leukemic cells, with the exception of the stem cells, is due to Imatinib
blocking the cells from dividing. The leukemic cells remain quiescent until they
reach the end of their lifespan. Given that, with the exception of the stem cells,
all blood cells are relatively short-lived (one day to several months, depending on
the type of cell [32]), all such cells will slowly die out leaving only, as a residue,
the very long-lived leukemic stem cells. We assume that Imatinib does affect stem
cells exactly in the same way as it acts on all other leukemic cells. The different
life-spans of different types of cells is what leads to different outcomes. This does
not contradict the results of the experiments mentioned earlier [35, 67], where it
appears that Imatinib is unable to deplete the LSCs: indeed Imatinib shifts the
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LSCs to a quiescent state. As soon as the treatment is discontinued, the LSCs
generally resume their cycling activity, which causes the observed relapse.
From observation 3 of Section 6.2 we note that relapses seem to occur over a
period of five years; however it has been estimated that it takes approximately 5-7
years for CML to reach detection size [49, 53, 73]. Thus if random point mutations
causing drug resistance could happen during treatment (due to the continuing divi-
sion of LSCs), then we should see various cases of patients having relapses well after
five years from the start of the therapy. This does not appear to be the case [45].
This observation should be viewed as another argument that the drug is able to
shut down the cycling mechanism among the leukemic stem cells putting them in
a quiescent state. If this were not the case, there would still be production of drug
resistant stem cells, due to the random mutation mechanism which is always acting
on each cell division. Note that this is another example of what drug resistance can
tell us about cancer, in addition to our results on the division pattern of the LSCs
we obtained in Chapter 4.
Now, if we assume that Imatinib blocks all leukemic cells from dividing, then
we come to the conclusion that there are two possible scenarios: either a patient has
already drug resistant LSCs present at detection, which should cause a relapse in the
future, or he/she does not, in which case a relapse is not expected, at least not due
to this type of drug resistance. Indeed once the treatment starts, no more mutations
are produced because LSCs do not divide anymore due to the presence of Imatinib.
Thus the creation (or lack) of resistant mutants in the leukemic stem cell compart-
ment before the therapy starts will generally determine the long-term outcome for a
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patient continuously under treatment with Imatinib. It is natural, however, to ex-
pect some patient-level variability in the effectiveness of Imatinib in blocking LSCs
from dividing, due to the factors like dosing schedules, drug pharmacokinetics, and
patient-specific characteristics.
We would like to mention that such an assumption leaves the door open to
the possibility of a complete eradication of the disease. Indeed, unless the LSCs are
eternal, sooner or later they should die out. Furthermore the immune system may
have an important role during therapy in eliminating this quiescent LSC residue [55].
6.5 Insights for the diagnostic and therapeutic strategies in CML
We have elucidated the reasons why our new hypothesis is capable of explaining
the current data on CML better than all other previous assumptions made in the
existing literature. Based on this hypothesis, we now use the mathematical results
of Chapter 4 to obtain new insights on the dynamics of the development of drug
resistance in CML and to provide an important recommendation for the standard
medical practice, when dealing with CML.
Recall that the dynamics of the averaged behavior of the wild-type cancer stem
cell populations, denoted by S(t), can be described using the following equation (see
system 4.4):
S ′(t) = [L(1− a− 2b)−D]S(t). (6.1)
Note that we are assuming that the stem cell population is growing exponen-
tially. However, this is a realistic assumption for CML that is detected at an early
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Figure 6.3: Growth curve for the leukemic stem cell population, where
the exponential rate constant is [L(1 − a − 2b) − D] ≈ 2.49. Time t is
measured in years.
stage. Indeed, as previously mentioned, if there were to be a saturation level, it
should be reached much after the detection time.
It is estimated that the number of leukemic stem cells found in the case of an
early detection of CML is on the order of M ≈ 2.5 · 105 cells [47, 73]. It has also
been estimated that it takes approximately 5-7 years for CML to reach detection
size [49, 53, 73]. Thus if we set, for example, S(5) = 2.5 · 105 , where time is
measured in years, we obtain from equation (6.1) that [L(1− a− 2b)−D] ≈ 2.49.
The exponential growth of such leukemic stem cell population up to detection size
is depicted in Figure 6.3.
It is interesting to note that according to this curve, if drug resistance occurs
in the five years before detection, it will occur in the last year with a probability of
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approximately 0.92, in the last six months with a probability of 0.7, and in the last
three and a half months with a probability of 0.5. This is due to the fact that, for
example, after four years the number of leukemic stem cells is approximately equal
to 21, 000, which is only about 8% of the total population found at the end of the
fifth year (detection time).
This calculation has fundamental consequences for the standard of practice
in the diagnostic and therapeutic strategies of CML. Indeed, with the hypothesis
that Imatinib blocks all leukemic cells from dividing, then, as we already mentioned,
either a patient has already developed drug resistance in the LSC compartment at
detection, which will generally cause a future relapse, or he/she does not, in which
case a relapse is not expected, at least not due to this type of drug resistance.
Thus having drug-resistant mutants in the leukemic stem cell compartment before
the therapy starts will determine the expected long-term outcome. This argument
translates into a clear need to start the treatment as soon as possible, in order to
stop the occurrence of further LSC divisions, which have the risk of creating drug-
resistant LSCs. Moreover, it is critical to detect CML before the occurrence of drug
resistance. As demonstrated, if a random point mutation causing the insurgence
of resistance hits a leukemic stem cell, it is most likely to occur in the last several
months before detection. It is therefore essential to detect CML as early as possible.
Detecting CML even only a few weeks earlier could potentially make a substantial
difference on the expected final outcome of the disease.
Interestingly, we would like to note that this approach is not, in general, fol-
lowed by the standard medical practice, when dealing with CML. To the contrary,
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it is often assumed that the time of detection of CML has no connection with pos-
sible future relapses. The development of resistance is not assumed to be related
to a late detection or a delay in the start of the treatment. This is the opposite
of what we conclude by studying the dynamics of the development of CML under
Imatinib and the related problem of drug resistance. In conclusion, we suggest that





In this dissertation we have considered the dynamics of drug resistance in
cancer and the related issue of the dynamics of cancer stem cells. After introducing
the relevant biological aspects needed for the mathematical modeling of these topics
in Chapter 1, we reviewed the existing mathematical modeling literature on cancer
stem cells and drug resistance in Chapter 2.
In Chapter 3 we considered the question of the dependence - or not - of the
dynamics of drug resistance on the so called “turnover rate”, a variable which is an
indicator of the relative frequency of cell division with respect to cell death. Here
our focus is on resistance which is caused only by random genetic point mutations.
A very simple system of ODEs allows us to obtain results comparable to those
found in the literature with one important difference. Indeed we have shown that
the amount of resistance that is generated before the beginning of the treatment,
and which is present at some given time afterward, always depends on the turnover
rate, no matter how many drugs are used.
In Chapter 4 we developed a new methodology in order to derive an estimate
of the probability of developing resistance to drugs by the time a tumor is diagnosed.
Importantly, the heterogeneity of the cancer population is taken into account. More-
over, in the case of CML, we were able to infer the preferred mode of division of the
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hematopoietic cancer stem cells, predicting a large shift from asymmetric division
to symmetric renewal. From a methodological perspective, the mathematical anal-
ysis has allowed us to use indirect information about the mechanisms that control
the dynamics of the disease evolution to reach specific conclusions that go beyond
the present reach of experiments. While we have applied our mathematical results
to the available clinical data on CML, the approach is not limited to this specific
disease, and we expect similar conclusions about the division of cancer stem cells in
other types of cancer as well. Specifically, our model should apply to any cancer for
which stem cells our known to be the driving force of the progression of the disease
and for which point mutations are a source of drug resistance. It could be of great
interest if our results were to be tested experimentally, at least in vitro, on cancer
cell lines. Ideally, a direct experimental method would require isolating cancer stem
cells and healthy stem cells and compare the growth of both stem cell populations.
In Chapter 5 we extended the results of Chapter 4 by relaxing the assumptions
on the average growth of the tumor, thus going beyond the standard exponential
case. We calculated the probability that by the time a tumor reaches detection size,
there are drug resistant stem cells in a cancer population growing logistically. We
found that this probability is the same as for the exponential growth case. We would
like to note that arguably our modeling methodology may be seen as more general,
in the sense that, at least for the wild-type population, we only made assumptions
on their averaged behavior. Moreover we showed that our results may be a good
approximation also for a much more general form of tumor growth.
Finally, in Chapter 6 we reviewed the basic modeling assumptions and main
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results found in the mathematical modeling literature on CML, and have formulated
a new hypothesis on the effects that the drug Imatinib has on leukemic stem cells.
Specifically, we have hypothesized that Imatinib is able to stop LSCs from dividing,
putting them in a quiescent state. We have elucidated the reasons why this hypoth-
esis is capable of explaining the current data on CML better than all other previous
assumptions made in the existing literature. Based on this hypothesis, we then used
the mathematical results of Chapter 4 to obtain new insights on the dynamics of the
development of drug resistance in CML. We concluded with converting the mathe-




[1] J. L. Abkowitz, M. T. Persik, G. H. Shelton, R. L. Ott, J. V. Kiklevich, S. N.
Catlin, and P. Guttorp. Behavior of hematopoietic stem cells in a large animal.
Proc Natl Acad Sci USA, 92:2031–2035, 1995.
[2] P. Armitage and R. A. Doll. The age distribution of cancer and a multi-stage
theory of carcinogenesis. Br J Cancer, 8:1–12, 1954.
[3] K. B. Athreya and P. E. Ney. Branching Processes. Springer, Berlin, 1972.
[4] B. G. Birkhead, E. M. Rakin, S. Gallivan, L. Dones, and R. D. Rubens.
A mathematical model of the development of drug resistance to cancer
chemotherapy. Eur. J. Cancer Clin. Oncol., 23:1421–1427, 1987.
[5] C. Booth and C. S. Potten. Gut instincts: Thoughts on intestinal epithelial
stem cells. J Clin Invest, 105:1493—1499, 2000.
[6] S. Branford, T. P. Hughes, and Z. Rudzki. Monitoring chronic myeloid
leukaemia therapy by real-time quantitative pcr in blood is a reliable alterna-
tive to bone marrow cytogenetics. British Journal of Haematology, 107:587–
599, 1999.
[7] S. Branford, Z. Rudzki, S. Walsh, I. Parkinson, A. Grigg, J. Szer, K. Tay-
lor, R. Herrmann, J. F. Seymour, C. Arthur, D. Joske, K. Lynch, and
T. Hughes. Detection of bcr-abl mutations in patients with cml treated
with imatinib is virtually always accompanied by clinical resistance, and
mutations in the atp phosphate-binding loop (p-loop) are associated with
apoorprognosis.blood102,276—283(2003). Blood, 102:276–283, 2003.
[8] L. L. Campbell and K. Polyak. Breast tumor heterogeneity. Cell Cycle,
6(19):2332–2338, 2007.
[9] L. Cojocaru and Z. Agur. A theoretical analysis of interval drug dosing for
cell-cycle-phase-specific drugs, math. biosci., 109 (1992), 85–97. Math. Biosci.,
109:85–97, 1992.
[10] A. J. Coldman and J. H. Goldie. Role of mathematical modeling in protocol
formulation in cancer chemotherapy. Cancer Treat Rep, 69:1041–1048, Oct
1985.
[11] A. J. Coldman and J. H. Goldie. A stochastic model for the origin and treat-
ment of tumors containing drug-resistant cells. Bull. Math. Biol., 48:279–292,
1986.
[12] J. Cortes, S. O’Brien, and H. Kantarjian. Discontinuation of imatinib therapy
after achieving a molecular response. Blood, 104:2204—2205, 2004.
106
[13] M. Dean, T. Fojo, and S. Bates. Tumor stem cells and drug resistance. Nat
Rev Cancer, 5:275–284, 2005.
[14] B. F. Dibrov. Resonance effect in self-renewing tissues. J Theor Biol, 192:15–
33, 1998.
[15] D. Dingli, A. Traulsen, and F. Michor. (A)Symmetric stem cell replication
and cancer. PLoS Comput Biol, 3(3):e53, 2007.
[16] Michor F Dingli D. Successful therapy must eradicate cancer stem cells. Stem
Cells, 24:2603–2610, 2006.
[17] A. d’Onofrio and I. P. Tomlinson. A nonlinear mathematical model of cell
turnover, differentiation and tumorigenesis in the intestinal crypt. J Theor
Biol, 244:367–374, 2007.
[18] J. W. Drake and J. J. Holland. Mutation rates among rna viruses. Proc Natl
Acad Sci USA, 96(1):13910–13913, 1999.
[19] B. J. Druker, S. Tamura, E. Buchdunger, S. Ohno, G. M. Segal, S. Fanning,
J. Zimmermann, and N. B. Lydon. Effects of a selective inhibitor of the abl
tyrosine kinase on the growth of bcr-abl positive cells. Nat Med, 2:561–566,
1996.
[20] R. Durrett and S. Moseley. Evolution of resistance and progression to disease
during clonal expansion of cancer. Theor Pop Biol, 77:42–48, 2010.
[21] H. Enderling, M. A. Chaplain, A. R. Anderson, and J. S. Vaidya. A mathe-
matical model of breast cancer development, local treatment and recurrence.
J Theor Biol, 246:245–259, 2007.
[22] J. C. Fisher. Multiple-mutation theory of carcinogenesis. Nature, 181:651–652,
1958.
[23] J. Foo, M. W. Drummond, B. Clarkson, T. Holyoake, and F. Michor. Erad-
ication of chronic myeloid leukemia stem cells: A novel mathematical model
predicts no therapeutic benefit of adding g-csf to imatinib. PLoS Comput Biol,
5(9):e1000503. doi:10.1371/journal.pcbi.1000503, 2009.
[24] E. Frei, B. A. Teicher, S. A. Holden, K. N. Cathcart, and Y. Y. Wang. Pre-
clinical studies and clinical correlation of the effect of alkylating dose. Cancer
Res., 48:6417–6423, Nov 1988.
[25] E. A. Gaffney. The application of mathematical modelling to aspects of adju-
vant chemotherapy scheduling. J Math Biol, 48:375—422, 2004.
[26] E. A. Gaffney. The mathematical modelling of adjuvant chemotherapy
scheduling: incorporating the effects of protocol rest phases and pharmacoki-
netics. Bull. Math. Biol., 67:563–611, 2005.
107
[27] R. Gatenby. A change of strategy in the war on cancer. Nature, 459:508–509,
2009.
[28] B. Giebel, T. Zhang, J. Beckmann, J. Spanholtz, P. Wernet, A. D. Ho, and
M. Punzel. Primitive human hematopoietic cells give rise to differentially
specified daughter cells upon their initial cell division. Blood, 107:2146—2152,
2006.
[29] J. H. Goldie and A. J. Coldman. A mathematic model for relating the drug
sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep,
63:1727–1733, 1979.
[30] J. H. Goldie and A. J. Coldman. A model for resistance of tumor cells to
cancer chemotherapeutic agents. Math. Biosci., 65:291–307, 1983.
[31] J. H. Goldie and A. J. Coldman. Quantitative model for multiple levels of
drug resistance in clinical tumors. Cancer Treat Rep, 67:923–931, Oct 1983.
[32] J. H. Goldie and A. J. Coldman. Drug Resistance in Cancer: Mechanisms
and Models. Cambridge University Press, Cambridge, 1998.
[33] J. H. Goldie, A. J. Coldman, and G. A. Gudauskas. Rationale for the use of
alternating non-cross-resistant chemotherapy. Cancer Treat Rep, 66:439–449,
Mar 1982.
[34] M. M. Gottesman. Mechanisms of cancer drug resistance. Annu. Rev. Med.,
53:615—27, 2002.
[35] S. M. Graham, H. G. Jørgensen, E. Allan, C. Pearson, M. J. Alcorn, L. Rich-
mond, and T. L. Holyoake. Primitive, quiescent, philadelphia-positive stem
cells from patients with chronic myeloid leukemia are insensitive to sti571 in
vitro. Blood, 99:319–325, 2002.
[36] W. M. Gregory, B. G. Birkhead, and R. L. Souhami. A mathematical model
of drug resistance applied to treatment for small-cell lung cancer. J. Clin.
Oncol., 6:457–461, 1988.
[37] D. P. Griswold, M. W. Trader, E. Frei III, W. P. Peters, M. K. Wolpert, and
W. R. Laster. Response of drug-sensitive and -resistant l1210 leukemias to
high-dose chemotherapy. Cancer Res, 47:2323–2327, 1987.
[38] F. Guilhot, B. Druker, R. A. Larson, I. Gathmann, C. So, R. Waltzman, and
S. G. O’Brien. High rates of durable response are achieved with imatinib
after treatment with interferon plus cytarabine: results from the interna-
tional randomized study of interferon and sti571 (iris) trial. Haematologica,
94(12):1669—1675, Dec 2009.
[39] H. Haeno, Y. Iwasa, and F. Michor. The evolution of two mutations during
clonal expansion. Genetics, 177:2209–2221, 2007.
108
[40] H. Haeno, R. L. Levine, D. G. Gillilandd, and F. Michor. A progenitor cell
origin of myeloid malignancies. Proc Natl Acad Sci USA, 106(39):16616–16621,
2009.
[41] D. Hanahan and R. A. Weinberg. The hallmarks of cancer. Cell, 100:57–70,
2000.
[42] L. E. Harnevo and Z. Agur. The dynamics of gene amplification described as
a multitype compartmental model and as a branching process. Math. Biosci.,
103:115–138, 1991.
[43] L. E. Harnevo and Z. Agur. Use of mathematical models for understanding
the dynamics of gene amplification, mutat. res., 292 (1993), 17–24. Mutat.
Res., 292:17–24, 1993.
[44] G. H. Heppner. Tumor heterogeneity. Cancer Res, 44:2259–2265, 1984.
[45] A. Hochhaus, S. G. O’Brien, F. Guilhot, B. J. Druker, S. Branford, L. Foroni,
J. M. Goldman, M. C. Muller, J. P. Radich, M. Rudoltz, M. Mone, I. Gath-
mann, T. P. Hughes, R. A. Larson, T. Hughes, K. Taylor, S. Durant,
A. Schwarer, D. Joske, J. Seymour, A. Grigg, D. Ma, C. Arthur, K. Bradstock,
D. Joshua, H. Agis, G. Verhoef, A. Louwagie, P. Martiat, A. Bosly, J. Shep-
herd, C. Shistok, J. Lipton, D. Forrest, I. Walker, D. C. Roy, M. Rubinger,
I. Bence-Bruckler, D. Stewart, M. Kovacs, A. R. Turner, J. Nielsen, H. Birgens,
O. Bjerrum, P. Rousselot, J. Reiffers, T. Facon, J. L. Harousseau, M. Tulliez,
A. Guerci, D. Blaise, F. Maloisel, M. Michallet, T. Fischer, A. Hochhaus,
R. Andreesen, C. Nerl, M. Freund, N. Gattermann, G. Ehninger, D. Nieder-
wieser, O. G. Ottmann, C. Peschel, A. D. Ho, A. Neubauer, P. le Coutre,
W. Aulitzky, G. Saglio, M. Baccarani, R. Fanin, G. Rosti, F. Mandelli, M. Laz-
zarino, E. Morra, A. Carella, M. Petrini, F. Nobile, V. Liso, F. Ferrara, V. Riz-
zoli, G. Fiortoni, G. Martinelli, J. Cornelissen, G. Ossenkoppele, P. Browett,
T. Gedde-Dahl, J. M. Tangen, I. Dahl, F. Cervantes, J. Odrizoala, J. C.
Hernandez Boulda, J. L. Steegmann, C. Canizo, J. Diaz, A. Grenena, M. Fer-
nandez, B. Simonsson, L. Stenke, C. Paul, M. Bjoreman, C. Malm, H. Waden-
vik, P. G. Nilsson, I. Turesson, A. Gratwohl, U. Hess, M. Solenthaler, J. M.
Goldman, R. E. Clark, A. Green, T. Holyoake, G. Lucas, G. Smith, D. Mil-
ligan, S. Rule, A. Burnett, H. Kantarjian, R. Silver, R. Stone, B. Powell,
J. Gabrilove, R. Moroose, M. Wetzler, J. Bearden, S. Cataland, I. Rabi-
nowitz, B. Meisenberg, K. Thompson, S. Graziano, P. Emanuel, H. Gross,
P. Cobb, R. Bhatia, S. Dakhil, A. D. Irwin, B. Issell, S. Pavletic, P. Kue-
bler, E. Layhe, P. Butra, J. Glass, J. Moore, B. Grant, H. Neill, R. Herzig,
H. Burris, B. Petersen, M. Kalaycio, D. Stirewalt, W. Samlowski, E. Berman,
S. Limentani, T. Seay, T. Shea, L. Akard, G. Smith, P. Becker, S. Devine,
R. Hart, R. Veith, J. Wade, M. Brunvad, L. Kalman, D. Strickland, M. Shu-
rafa, A. Bashey, R. Shadduck, H. Safah, M. Rubenstein, R. Collins, A. Keller,
M. Tallman, A. Pecora, M. Agha, H. Homes, R. Guidice, B. J. Druker, F. Guil-
hot, R. A. Larson, S. O’Brien, J. Rowe, C. A. Schiffer, M. Buyse, M. Baccarani,
109
F. Cervantes, J. Cornelissen, T. Fischer, A. Hochhaus, T. Hughes, K. Lechner,
J. L. Nielsen, J. Reiffers, P. Rousselot, G. Saglio, J. Shepherd, B. Simonsson,
A. Gratwohl, J. M. Goldman, M. Talpaz, K. Taylor, and G. Verhoef. Six-year
follow-up of patients receiving imatinib for the first-line treatment of chronic
myeloid leukemia. Leukemia, 23:1054–1061, Jun 2009.
[46] M. S. Holtz, M. L. Slovak, F. Zhang, C. L. Sawyers, S. J. Forman, and R. Bha-
tia. Imatinib mesylate (STI571) inhibits growth of primitive malignant pro-
genitors in chronic myelogenous leukemia through reversal of abnormally in-
creased proliferation. Blood, 99:3792–3800, 2002.
[47] T. Holyoake, X. Jiang, C. Eaves, and A. Eaves. Isolation of a highly quiescent
subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood,
94:2056–2064, Sep 1999.
[48] M. M. Horowitz, P. A. Rowlings, and J. R. Passweg. Allogeneic bone mar-
row transplantation for cml: A report from the international bone marrow
transplant registry. Bone Marrow Transplant, 17(Suppl. 3):S5–S6, 1996.
[49] M. Ichimaru, T. Ishimaru, M. Mikami, Y. Yamada, and T. Ohkita. Incidence
of leukemia in a fixed cohort of atomic bomb survivors and controls, Hiroshima
and Nagasaki October 1950 - December 1978. Technical Report RERF TR
13–81, Radiation Effects Research Foundation, Hiroshima, 1981.
[50] Y. Iwasa, M. A. Nowak, and F. Michor. Evolution of resistance during clonal
expansion. Genetics, 172:2557–2566, Apr 2006.
[51] M. D. Johnston, C. M. Edwars, W. F. Bodmer, P. K. Maini, and S. J. Chap-
man. Mathematical modeling of cell population dynamics in the colonic crypt
and in colorectal cancer. 104:4008-4013, 2007. Proc Natl Acad Sci USA,
104:4008–4013, 2007.
[52] M. D. Johnston, P. K. Maini, S. J. Chapman, C. M. Edwards, and W. F.
Bodmer. On the proportion of cancer stem cells in a tumour. J. Theor. Biol.,
266(4):708–711, 2010.
[53] H. G. Jorgensen and T. L. Holyoake. Characterization of cancer stem cells
in chronic myeloid leukaemia. Biochemical Society Transactions, 35(5):1347–
1351, 2007.
[54] P. N. Keller, A. Dakic, J. M. Adams, S. L. Nutt, and A. Strasser. Tumor
growth need not be driven by rare cancer stem cells. Science, 317:337, 2007.
[55] P. S. Kim, P. P. Lee, and D. Levy. Dynamics and potential impact of
the immune response to chronic myelogenous leukemia. PLoS Comput Biol,
4:e1000095 doi:10.1371/journal.pcbi.1000095, 2008.
110
[56] M. Kimmel and D. E. Axelrod. Mathematical models of gene amplification
with applications to cellular drug resistance and tumorigenecity. Genetics,
125:663–644, 1990.
[57] G. Klein. Reply to Bredberg: the voice of the whale. Proc Natl Acad Sci USA,
106:E52, 2009.
[58] N. Komarova. Stochastic modeling of drug resistance in cancer. J. Theor.
Biol., 239:351–366, Apr 2006.
[59] N. Komarova, A. A. Katouli, and D. Wodarz. Combination of two but not
three current targeted drugs can improve therapy of chronic myeloid leukemia.
PLoS One 4, 4:e4423, 2009.
[60] N. L. Komarova and D. Wodarz. Drug resistance in cancer: principles of
emergence and prevention. Proc. Natl. Acad. Sci. U.S.A., 102:9714–9719, Jul
2005.
[61] N. L. Komarova and D. Wodarz. Effect of cellular quiescence on the success
of targeted cml therapy. PLoS ONE, 2:e990, 2007.
[62] A. V. Krivtsov, D. Twomey, Z. Feng, M. C. Stubbs, Y. Wang, J. Faber,
J. E. Levine, J. Wang, W. C. Hahn, D. G. Gilliland, T. R. Golub, and S. A.
Armstrong. Transformation from committed progenitor to leukemia stem cell
initiated by mll-af9. Nature, 442:818–822, 2006.
[63] T. A. Kunkel and K. Bebenek. DNA replication fidelity. Annu. Rev. Biochem.,
69:497–529, 2000.
[64] C.-Y. Lee, K. J. Robinson, and C. Q. Doe. Lgl, pins and apkc regulate neu-
roblast self- renewal versus differentiation. Nature, 439:594–598, 2006.
[65] S. E. Luria and M. Delbruck. Mutations of Bacteria from Virus Sensitivity to
Virus Resistance. Genetics, 28:491–511, Nov 1943.
[66] W.J. Mackillop, A. Ciampi, J.E. Till, and R. N. Buick. A stem cell model of
human tumor growth: implications for tumor cell clonogenic assays. Journal
of the National Cancer Institute, 70(1):9–16, January 1983.
[67] F. X. Mahon, F. Belloc, V. Lagarde, C. Chollet, F. Moreau-Gaudry, J. Reiffers,
J. M. Goldman, and J. V. Melo. Mdr1 gene overexpression confers resistance
to imatinib mesylate in leukemia cell line models. Blood, 101:2368—2373,
2003.
[68] F. McCormick. New-age drug meets resistance. Nature, 412:281–282, 2001.
[69] J. L. McKenzie, O. I. Gan, M. Doedens, J. C. Wang, and J. E. Dick. Indi-
vidual stem cells with highly variable proliferation and self-renewal properties
comprise the human hematopoietic stem cell compartment. Nat. Immunol.,
7:1225–1233, Nov 2006.
111
[70] J. V. Melo and D. J. Barnes. Chronic myeloid leukaemia as a model of disease
evolution in human cancer. Nature Reviews Cancer 7, 7:441–453, 2007.
[71] L. M. F. Merlo, J. W. Pepper, B. J. Reid, and C. C. Maley. Cancer as an
evolutionary and ecological process. Nature Reviews Cancer, 6:924–935, 2006.
[72] F. Michor. Cml blast arises from progenitors. Stem Cells, 25:1114–1118, 2007.
[73] F. Michor, T. P. Hughes, Y. Iwasa, S. Branford, N. P. Shah, C. L. Sawyers,
and M. A. Nowak. Dynamics of chronic myeloid leukaemia. Nature, 435:1267–
1270, Jun 2005.
[74] F. Michor, Y. Iwasa, and M. A. Nowak. The age incidence of chronic myeloid
leukemia can be explained by a one-mutation model. Proc Natl Acad Sci USA,
103:14931—14934, 2006.
[75] F. Michor, Y. Iwasa, H. Rajagopalan, C. Lengauer, and M. A. Nowak. Linear
model of colon cancer initiation. Cell Cycle, 3:358–362, 2004.
[76] C. Mode. Multitype Branching Processes. American Elsevier Publishing Com-
pany, New York, 1971.
[77] S. H. Moolgavkar. Carcinogenesis modeling: from molecular biology to epi-
demiology. Ann. Rev. Public Health, 7:151–169, 1986.
[78] S. J. Morrison and J. Kimble. Asymmetric and symmetric stem-cell divisions
in development and cancer. Nature, 441:1068–1074, Jun 2006.
[79] J. M. Murray. The optimal scheduling of two drugs with simple resistance for a
problem in cancer chemotherapy. IMA J. Math. Appl. Med. Bio., 14:283–303,
1997.
[80] S. Nakasu, Y. Nakasu, T. Fukami, J. Jito, and K. Nozaki. Growth curve
analysis of asymptomatic and symptomatic meningiomas. J Neurooncology,
DOI: 10.1007/s11060-010-0319-1, 2010.
[81] C. O. Nordling. A new theory on cancer-inducing mechanism. Br J Cancer,
7:68–72, 1953.
[82] L. Norton and R. Simon. The growth curve of an experimental solid tumor
following radiotherapy. J. Natl. Cancer Inst., 58(6):1735–1741, 1977.
[83] L. Norton and R. Simon. Tumor size, sensitivity to therapy, and design of
treatment schedules. Cancer Treat. Rep., 61(7):1307–1317, 1977.
[84] L. Norton and R. Simon. The norton-simon hypothesis revisited. Cancer
Treat. Rep., 70:163–169, 1986.
[85] P. C. Nowell. The clonal evolution of tumor cell populations. Science, 194:23–
28, 1976.
112
[86] S. G. O’Brien, F. Guilhot, R. A. Larson, I. Gathmann, M. Baccarani, F. Cer-
vantes, J. J. Cornelissen, T. Fischer, A. Hochhaus, T. Hughes, K. Lechner,
J. L. Nielsen, P. Rousselot, J. Reiffers, G. Saglio, J. Shepherd, B. Simon-
sson, A. Gratwohl, J. M. Goldman, H. Kantarjian, K. Taylor, G. Verhoef,
A. E. Bolton, R. Capdeville, B. J. Druker, and IRIS Investigators. Ima-
tinib compared with interferon and low-dose cytarabine for newly diagnosed
chronic-phase chronic myeloid leukemia. iris investigators. N Engl J Med,
348:994–1004, 2003.
[87] G. Ou, N. Stuurman, M. D’Ambrosio, and R. D. Vale. Polarized myosin
produces unequal-size daughters during asymmetric cell division. Science,
DOI: 10.1126/science.1196112, September 2010.
[88] J. C. Panetta. A mathematical model of drug resistance: heterogeneous tu-
mors. Math. Biosci., 147(1):41–61, 1998.
[89] J. C. Panetta and J. Adam. A mathematical model of cycle-specific chemother-
apy. Mathl. Comput. Modelling, 22:67—82, 1995.
[90] A. Pappenheim. Prinzipien der neuen morphologischen haematologie nach
zytogenetischer grundlage. Folia Haematol, 21:91–101, 1917.
[91] S. Y. Park, M. Gonen, H. J. Kim, F. Michor, and K. Polyak. Cellular and
genetic diversity in the progression of in situ human breast carcinomas to an
invasive phenotype. J Clin Invest., 120(2):636–644, 2010.
[92] M. C. Perry. The Chemotherapy Source Book. Lippincott Williams & Wilkins,
Philadelphia, 4th edition, 2008.
[93] K. Polyak and W. C. Hahn. Roots and stems:stem cells in cancer. Nat Med,
12:296–300, 2006.
[94] E. Quintana, M. Shackleton, M. S. Sabel, D. R. Fullen, T. M. Johnson, and
S. J. Morrison. Efficient tumor formation by single human melanoma cells.
Nature, 456:593–598, 2008.
[95] R. P. Regala, C. Weems, L. Jamieson, A. Khoor, E. S. Edell, C. M. Lohse,
and A. P. Fields. Atypical protein kinase c iota is an oncogene in human non-
small cell lung cancer. Cancer Res, 65:8905–8911, 2005.
[96] R. Ren. Mechanisms of bcr-abl in the pathogenesis of chronic myelogenous
leukaemia. Nat Rev Cancer, 5:172—183, 2005.
[97] T. Reya, S. J. Morrison, M. F. Clark, and I. L. Weissman. Stem cells, cancer,
and cancer stem cells. Nature, 414:105–111, 2001.
[98] I. Roeder, M. Horn, I. Glauche, A. Hochhaus, M. C. Mueller, and M. Loeffler.
Dynamic modeling of imatinib-treated chronic myeloid leukemia: functional
insights and clinical implications. Nat. Med., 12:1181–1184, Oct 2006.
113
[99] C. L. Sawyers. Calculated resistance in cancer. Nat. Med., 11:824–825, 2005.
[100] R. T. Schimke. Gene amplification, drug resistance, and cancer. Cancer Res,
44:1735—1742, 1984.
[101] R. T. Schimke. Gene amplification in cultured cells. J. Biol. Chem., 263:5989—
5992, 1988.
[102] T. Schindler, W. Bornmann, P. Pellicena, W. T. Miller, B. Clarkson, and
J. Kuriyan. Structural mechanism for sti-571 inhibition of abelson tyrosine
kinase. Science, 289:1938–1942, 2000.
[103] H. E. Skipper, F. M. Schabel, and H. Lloyd. Dose-response and tumor cell
repopulation rate in chemotherapeutic trials., volume 1 of Advances in Cancer
Chemotherapy, pages 205–253. Marcel Dekker, New York, 1979.
[104] H. E. Skipper, F. M. Schabel, and W. S. Wilcox. Experimental evaluation of
potential anticancer agents. xiii. on the criteria and kinetics associated with
“curability” of experimental leukemia. Cancer Chemother. Rep., 35:1–111,
1964.
[105] R. L. Souhami, W. M. Gregory, and B. G. Birkhead. Mathematical models in
high-dose chemotherapy. Antibiot Chemother, 41:21–28, 1988.
[106] C. H. Takimoto and E. Calvo. Principles of oncologic pharmacotherapy. In
R. Pazdur, L. D. Wagman, K. A. Camphausen, and W. J. Hoskins, editors,
Cancer Management: A Multidisciplinary Approach. UBM medica, 2008.
[107] B. T. Tan, C. Y. Park, L. E. Ailles, and I. L. Weissman. The cancer stem cell
hypothesis: a work in progress. Laboratory Investigation, 86:1203–1207, 2006.
[108] B. A. Teicher. Cancer Drug Resistance. Humana Press, Totowa, NJ, 2006.
[109] J. E. Till, E. A. McCulloch, and L. Siminovitch. Stochastic model of stem cell
proliferation based on the growth of spleen colony forming cells. Proc Natl
Acad Sci USA, 1964:29–36, 51.
[110] A. J. Tipping, F. X. Mahon, V. Lagarde, J. M. Goldman, and J. V. Melo.
Restoration of sensitivity to sti571 in sti571-resistant chronic myeloid leukemia
cells. Blood, 98(13):3864–3867, 2001.
[111] T. D. Tlsty, B. H. Margolin, and K. Lum. Differences in the rates of gene
amplification in nontumorigenic and tumorigenic cell lines as measured by
Luria-Delbrück fluctuation analysis. Proc. Natl. Acad. Sci. U.S.A., 86:9441–
9445, Dec 1989.
[112] C. Tomasetti and D. Levy. Drug resistance always depends on the turnover
rate. In K. E. Herold and W. E. Bentley, editors, IFMBE Proceedings, vol-
ume 32, College Park, MD, 2010. Springer.
114
[113] C. Tomasetti and D. Levy. An elementary approach to modeling drug resis-
tance in cancer. Mathematical Biosciences and Engineering, 7(4), 2010.
[114] C. Tomasetti and D. Levy. Role of symmetric and asymmetric division of stem
cells in developing drug resistance. Proc Natl Acad Sci USA, 107(39):16766–
16771, 2010.
[115] J. Vardiman, N. Harris, and R. Brunning. The world health organization (who)
classification of the myeloid neoplasms. Blood, 100(7):2292—2302, 2002.
[116] H. Varmus. The new era in cancer research. Science, 312:1162–1165, 2006.
[117] G. F. Webb. Resonance phenomena in cell population chemotherapy models.
Rocky Mountain J. Math., 20:1195—1216, 1990.
[118] M. Wu, H. Y. Kwon, F. Rattis, J. Blum, C. Zhao, R. Ashkenazi, T. L. Jackson,
N. Gaiano, T. Oliver, and T. Reya. Imaging hematopoietic precursor division
in real time. Cell Stem Cell, 1:541–554, Nov 2007.
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